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CHAPTER I 
 
INTRODUCTION 
 
Glucose Homeostasis and the Glucose-6-Phosphatase Enzyme System 
 Glucose is a molecule critical to myriad organ systems throughout the body. In 
order to maintain optimal function of these systems, glucose must circulate in the 
bloodstream within a rather narrow concentration range. Homeostatic mechanisms exist 
to return the concentration to the normal range when deviations occur. Significant 
contributions to maintaining this balance are made by the liver whether the body is fed 
(postprandial) or fasted (preprandial). In a postprandial state when glucose is abundant, 
the liver and muscle can simply store glucose in its long-chain form of glycogen, or it can 
be converted to glucose-6-phosphate (G6P) and metabolized via glycolysis or the pentose 
phosphate pathway. Such actions serve to keep circulating blood glucose levels from 
rising too high above normoglycemia. The opposite, low glucose abundance, is found in 
the preprandial state; here the liver must produce glucose to reintroduce to the 
bloodstream by degrading glycogen stores or from precursors to gluconeogenesis. These 
include glycerol, amino acids, and lactate, and without these liver homeostatic 
mechanisms, organ systems such as the brain and central nervous system would cease to 
operate properly. 
These two processes, glycogenolysis and gluconeogenesis, are each tightly 
regulated by their own array of hormones and metabolites, but converge at G6P, which is 
hydrolyzed in the final step of glucose production in the liver to glucose and inorganic 
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phosphate. The responsible enzyme was first theorized due to the necessity for removal 
of the phosphate from G6P following glycogenolysis to create glucose. Glucose-6-
phosphatase activity was eventually demonstrated in the endoplasmic reticulum (ER) of 
hepatocytes, but the enzyme was unable to be isolated at this time due to its incorporation 
in the ER membrane and the instability inherent in membrane-bound proteins [1, 2]. 
Finally, cloning of the cDNA encoding the glucose-6-phosphatase catalytic subunit 
(G6pc) was accomplished by screening a murine liver cDNA library with representative 
probes of mRNA populations from wild type or mutant mice possessing deletions at the 
locus for albinism associated with reduced gluconeogenic enzyme activity [3-5]. This 
resulted in isolation of murine G6pc cDNA [4, 6]. 
Demonstration of the hydrolysis of glucose-6-phosphate in the ER membrane of 
hepatocytes, paired with the discovery of the G6pc cDNA, led to the development of the 
currently accepted model of glucose-6-phosphatase as a multi-component enzyme system 
that comprises a catalytic subunit and transporters for both substrate and product (Fig. 
1.1) [7, 8]. The catalytic subunit of this so-called Arion substrate-transport hypothesis, 
named after the group responsible for the microsomal analyses, lays in the membrane of 
the ER, with an inward, lumenal facing active site, while the opposite orientation is found 
in the fetus [9]. This model requires the presence of transporters to facilitate movement of 
substrate and products across the ER membrane; one such molecule, responsible for 
relocation of G6P to the ER lumen, was eventually identified and termed the G6P 
translocase (G6PT). Elucidation of this component of the glucose-6-phosphatase 
holoenzyme was made possible due to homology between mouse and human cDNAs and 
a known bacterial G6P transporter in Escherichia coli, UhpT [10]. Previous experiments  
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Figure 1.1.  Arion model of the glucose-6-phosphatase multicomponent enzyme 
system 
  
	   4 
have shown antiporter activity by UhpT [11], as well, lending credence to the hypothesis 
that G6PT serves to export inorganic phosphate product in addition to introducing G6P to 
the lumen of the ER [12]. At this time, the final component of the model, the glucose 
transporter, has not been identified. 
 
Disease States and Glucose-6-Phosphatase 
 In-depth investigation of this enzyme system is important due to association with 
human disease of either an increase or decrease in glucose-6-phosphatase activity. A 
deficiency in the activity of glucose-6-phosphatase results in multiple autosomal 
recessive disorders called glycogen storage disease (GSD) [13]. Persons suffering from 
GSD1a, caused by mutations in G6PC, experience fasted state hypoglycemia, increased 
glycogen deposition in liver and kidney, and other symptoms [14]. The remaining GSD 
variants, GSD1b and GSD1c, result from mutations in G6PT and demonstrate similar 
symptoms with an additional increased vulnerability to bacterial infection [15]. A basis 
for this susceptibility has been linked to dysfunctional neutrophils, which express G6PT 
but not G6PC, suggesting yet another role for the translocase. 
 A link between increased activity of glucose-6-phosphatase and disease has also 
been demonstrated, namely with type 2 and in poorly controlled cases of type 1 diabetes. 
These diseases are characterized by a multitude of symptoms, including elevated hepatic 
glucose production and ineffective peripheral glucose disposal, which result in 
hyperglycemia. Increased glucose-6-phosphatase activity in conjunction with increased 
mRNA levels has also been observed [16-18]. The reduced insulin signaling indicative of 
the diabetic state may be the cause, as an insulin responsive transcriptional unit has been 
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identified upstream of the transcriptional start site of G6PC, including a hepatocyte 
nuclear factor-1 (HNF-1) binding site from -231 to -199 [19] and two FOXO1 binding 
sites between -198 and -159 [20, 21]. While HNF-1 is considered to act as a stabilizer for 
FOXO1 binding [22, 23], direct targeting of FOXO1 by insulin signaling occurs [24-31]. 
In the context of G6PC, FOXO1 serves as a transcriptional activator, thus its exclusion 
from the nucleus following insulin activation results in decreased transcription of G6PC. 
Deficient signaling through the insulin receptor in type 2 diabetes allows for increased 
G6PC transcription and a worsened state of hyperglycemia. 
 
Isoforms of the Glucose-6-Phosphatase Gene Family 
 Initial interest in the activity of glucose-6-phosphatase and its role on glucose 
production was focused on the liver, though it has now been shown to be expressed and 
influence gluconeogenesis in other tissues as well, such as the kidney and small intestine. 
Glucose-6-phosphatase activity has also been observed in microsomes isolated from the 
β-cells of the pancreas, but at roughly one tenth that of liver microsomes [32]. While 
experiments have shown that rat islets express a protein capable of being bound by 
antibodies specific to glucose-6-phosphatase [33], the islet isoform displays a dissimilar 
enzymatic profile, namely Km value, pH optima, and inhibitor profile [32, 34]. These 
factors imply the presence of an islet-specific isoform or a tissue-specific regulatory 
factor capable of changing the kinetics of the liver enzyme. Upon the cloning of a cDNA 
from a mouse insulinoma library encoding a protein of similar weight and 50% identity to 
G6pc, it became apparent that a separate isoform existed. Further experiments established 
that this isoform was selectively expressed in the pancreatic Islets of Langerhans, 
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prompting the name islet-specific glucose-6-phosphatase catalytic subunit-related protein 
(IGRP), now commonly referred to as G6PC2 [32]. Based solely on its similarity in 
structure to G6PC, it would be predicted that G6PC2 would also be capable of 
hydrolyzing G6P; however, initial experiments using transient transfection of G6pc2 
failed to validate this hypothesis [32, 35-37]. By slightly altering the protocol conditions 
to minimize the disturbance when permeabilizing the intracellular membrane to G6P 
[38], G6pc2 was shown to hydrolyze G6P, albeit at a lower Km and VMAX than G6pc (Fig. 
1.2) [34]. 
 The advent of computer-based genetics research and the sequencing of the human 
genome have played a massive role in the search for new genes of interest, and the 
glucose-6-phosphatase gene family has not been exempt. Using the sequence for G6PC2 
as the query, a search was carried out using the BLAST search engine from NCBI, 
returning yet a third isoform of the gene family sharing 36% identity with G6PC. Upon 
discovery of its widespread expression, the protein was first dubbed the ubiquitously 
expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP), but is now 
known as G6PC3 [39]. Although demonstrating functional hydrolysis of G6P by G6PC3 
also initially proved difficult [39], glucose-6-phosphatase activity was eventually 
demonstrated through overexpression of G6PC3 by stable [40] or adenoviral [41] 
transfection. The defining characteristics of each isoform are illustrated in Table 1.1. 
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Figure 1.2.  Glucose-6-phosphatase activity observed by G6PC2 in permeabilized 
cells 
Using COS7 cells under a number of membrane permeabilization conditions, a measure 
of the glucose-6-phosphatase activity of G6PC2 was obtained. Cells were transfected 
with either a negative control pcDNA3.1 (white bars) or pcDNA3.1 containing the human 
G6PC2 (grey bars). Following transfection and a 48 hour incubation, the cells were 
harvested, pelleted, resuspended, and permeabilized with the listed technique. Each of 
these methods allows for limited disruption of the internal membranes of the cells, thus 
allowing for subsequent radiochemical assaying of glucose-6-phosphatase activity. F/T = 
freeze thawing; Soni. = sonication; Digi. = 0.1% digitonin for 15 min on ice; Ala. = 
0.02% alamethicin for 15 min on ice. Results are means ± S.E.M. [38] 
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Table 1.1.  The glucose-6-phosphatase catalytic subunit gene family 
 
Gene G6Pase 
Islet-Specific 
G6Pase-Related 
Protein (IGRP) 
Ubiquitous G6Pase 
Related Protein 
(UGRP) 
 G6PC G6PC2 G6PC3 
Tissue Liver Islet β-cell Ubiquitous 
Size 357 aa 355 aa 346 aa 
% Identity 100 50 36 
Chromosome 17q21 2 17q21 
Location ER ER ER 
#Transmembrane 
domains 9 9 9 
Substrate G6P G6P G6P 
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Islet-Specific Glucose-6-Phosphatase Activity 
 As was previously noted, expression and activity of a glucose-6-phosphatase have 
been detected in organs in addition to the liver, namely the β-cells of the pancreas [42]. 
The resounding perception regarding the β-cells of the pancreas prior to this discovery 
held glucokinase to be the primary glucose sensor [43-46]. A new model for glucose 
stimulated insulin secretion (GSIS) has now been developed, incorporating this islet-
specific glucose-6-phosphatase activity as a regulator of insulin secretion [47]. GSIS 
occurs as the concentration of glucose in the blood rises above normoglycemia, usually in 
the postprandial state. As this occurs, the glucose concentration outside the β-cell rises 
above that of the cytosol, allowing passive transport of glucose into the β-cell through 
GLUT2. Glucose is then phosphorylated by glucokinase and continues metabolism by 
entering glycolysis and the tricarboxylic acid (TCA) cycle (Fig. 1.3). The resulting 
products include ATP, increasing the concentration of ATP in the β-cell as well as the 
ratio of ATP to ADP. This shift causes the ATP-sensitive potassium (KATP) channels to 
close, inhibiting potassium inflow and depolarizing the membrane in the process. In 
response to this depolarization, voltage-gated calcium channels open to allow influx of 
calcium, which, when combined with intracellular calcium stores, activates the exocytotic 
machinery and facilitates fusion of insulin vesicles with the plasma membrane for 
secretion. 
Changes in insulin secretion must correspond appropriately to the varying 
concentrations of circulating glucose, and this process is inextricably linked due to the 
control exhibited by glucose metabolism on insulin exocytosis. As mentioned above, 
glucokinase [48] had been thought to act as the β-cell sensor for glucose with  
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Figure 1.3.  Futility of the glucose-6-phosphatase in the pancreatic β-cell 
The opposition of the activity of glucokinase in the β-cell by a glucose-6-phosphatase in 
the form of G6PC2 creates a futile cycle of ATP hydrolysis without replenishment. Such 
a depletion would decrease insulin secretion and, in turn, increase the concentration of 
plasma glucose. 
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experimental evidence in multiple models supporting this [43-46]. Previous 
considerations of GLUT1 and GLUT2 as potential glucose sensors [49, 50] were 
dismissed after neither a significant increase in GLUT1 nor a reduction of GLUT2 
expression by 90% affected GSIS in transgenic mice [45, 51]. However, the recent details 
discovered regarding the islet-specific glucose-6-phosphatase activity within the β-cells 
confound the supported model. The presence of an enzyme such as this counteracts the 
action of glucokinase and creates a futile cycle in the β-cell with a net product of 
hydrolyzed ATP between the two enzyme functions. By decreasing the pool of G6P 
available for GSIS, the ratio of ATP to ADP would also decrease and insulin secretion 
would be attenuated. The potential role of an islet-specific glucose-6-phosphatase as a 
negative component of the glucose sensor in the β-cell creates another point of regulation 
for maintaining normoglycemia through GSIS. Such a cycle has been seen to exist in an 
experimental setting using isolated islets from mice and rats, with varying percentages of 
glucose dephosphorylation occurring based on the characteristics of the animals from 
which the islets were isolated [52-54]. However, it has not yet been determined whether 
this result is indicative of variations in islet-specific glucose-6-phosphatase activity in 
vivo. 
 
Exploring the Role of G6pc2 in vivo 
 In an attempt to clarify the role of an islet-specific glucose-6-phosphatase, 
phenotypic analyses of G6pc2 knockout (KO) mice were carried out on a mixed genetic 
background [55], followed by pure genetic background analyses (Lynley Pound, Richard 
O’Brien, unpublished data). In both models, FPG was significantly reduced in both male 
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and female mice. A slight but significant reduction in fasting plasma cholesterol was also 
observed in the male and female KO mice on a pure C57BL/6J genetic background, 
consistent with a known association between levels of fasting glucose and cholesterol. A 
hypothesis was developed from these results, in which G6pc2 regulates GSIS as an 
inhibitory glucose sensor component in the β-cell. A futile substrate utilization cycle for 
ATP in this model would lead to a reduced ratio of ATP to ADP and decreased insulin 
secretion. Removal of G6pc2 from this system would thus allow unhindered GSIS to 
occur, resulting in a leftward shift of the S0.5 of GSIS, without a change in VMAX, and 
decreased FPG (Fig. 1.4). 
Numerous experiments were carried out to analyze GSIS in G6pc2 KO mice, 
including pancreas perfusions, intraperitoneal glucose tolerance tests (IPGTTs), and islet 
isolations (Lynley Pound, Richard O’Brien, unpublished data). Insulin secretion in 
response to various glucose concentrations was analyzed in situ from perfused pancreata. 
A sub-maximal glucose challenge of 6.5 mM led to secretion of ~252% more insulin in 
the pancreata of G6pc2 KO mice than WT pancreata, data that is consistent with the 
previously mentioned leftward shift in the dose response curve for GSIS in G6pc2 KO 
mice. In addition to the perfusion studies, IPGTTs were performed using G6pc2 KO and 
WT mice injected with a submaximal dose of 0.75 g/kg body weight dose of glucose. 
Mice deficient for G6pc2 had reduced blood glucose, but showed unchanged glucose 
tolerance and insulin secretion. Further support for a leftward shift in the GSIS dose 
response curve, but not a reduction in VMAX, was observed in static incubations of islets 
isolated from G6pc2 KO mice when compared to WT. Increases in GSIS of  
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Figure 1.4.  Hypothesized shift of GSIS response curve in animals lacking G6pc2 
Due to the proposed role of G6PC2 as a negative component of the glucose sensor in β-
cells, a leftward shift in the GSIS dose-response curve is expected to occur following 
deletion of G6pc2 in mice. Support for this model was observed through pancreas 
perfusions, IPGTTs, and islet isolations in G6pc2 KO mice. 
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approximately 2.2 fold were observed at both 5 mM and 11 mM glucose, while no 
difference in insulin secretion was observed at a maximal dose of 16.7 mM glucose. 
To better describe this shift in the response curve of GSIS, the sequestration of 
calcium into the ER of mice lacking G6pc2 was assessed. It has been previously 
suggested that one of the products of G6P hydrolysis in the ER lumen, inorganic 
phosphate, may be critical to the calcium sequestration process by forming calcium 
phosphate [56]. As was previously mentioned, these intracellar calcium stores combined 
with the influx of calcium following membrane depolarization form the basis of the 
activation of insulin exocytosis. In order to test this hypothesis, islets were isolated from 
male G6pc2 WT and KO mice and subsequently treated with thapsigargin (Lynley 
Pound, Richard O’Brien, unpublished data). Treatment with this compound results in the 
emptying of calcium from the sarco- and endoplasmic reticula of cells by inhibiting their 
corresponding calcium ATPases. Following thapsigargin addition, islets isolated from 
G6pc2 KO mice exhibited increased intracellular calcium emptying, indicating that these 
mice may have diminished endoplasmic reticulum-specific calcium retention. 
These results regarding retention of calcium suggest that deletion of G6pc2 would 
negatively impact sequestration of calcium in the ER. However, it was reasoned that any 
deficiency in β-cell function because of loss of G6pc2 would only be observed at high 
glucose concentrations because of the role of the sarco-/endoplasmic reticulum calcium 
ATPase (SERCA) pump in sequestering calcium in the ER [57, 58]. Therefore, IPGTTs 
were performed following a 6 hr fast using a 2.0 g/kg body weight dose of glucose in WT 
and G6pc2 KO mice, in which a slight impairment in glucose tolerance was observed in 
KO mice. Because negligible differences were observed in insulin sensitivity between 
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WT and G6pc2 KO mice through insulin tolerance tests, these data are indicative of a 
defect in β-cell function in G6pc2 KO mice that arises in a setting of high glucose 
concentration and leads to aberrant glucose tolerance. Support for this hypothesis was 
observed when measurement of insulin secretion in WT and G6pc2 KO mice following 
intraperitoneal injection of 2.0 g/kg body weight glucose yielded no change, indicating 
that mice deficient for G6pc2 fail to secrete sufficient insulin to regulate blood glucose 
levels. These data may explain the paradoxical GWA study data associating SNPs within 
G6PC2 with reduced FPG as well as a reduction in insulin secretion during glucose 
tolerance tests, despite a lack of consistent changes in insulin sensitivity [59-61]. Such a 
decrease in secretion of insulin may denote a change in calcium oscillation-driven 
pulsatility of insulin secretion [60, 62], as well as the previously mentioned deficiency in 
sequestration of calcium in the ER. 
Characterization of mice lacking G6pc2 has provided beneficial insight into the 
role G6pc2 plays in GSIS. Another study has also analyzed the converse protein status 
using a transgenic NOD mouse model that overexpresses human G6PC2 via the rat 
insulin promoter (RIP). However, this model was not informative because increased 
G6PC2 expression resulted in augmented ER stress, possibly due to the formation of 
unfolded proteins, causing cell death and eventually diabetes [63]. 
 
The Role of G6PC2 in Type 1 Diabetes 
 Also related to variations in FPG and G6PC2 are recent investigations of type 1 
diabetes and the immunology of the disease in the β-cell. In a mouse model of human 
type 1 diabetes, the non-obese diabetic (NOD) mouse [64], researchers found that G6PC2 
	   16 
acts as an autoantigen [65]; this was also observed in humans [66, 67] and “humanized 
mice” [66, 68, 69]. As the pathophysiology of type 1 diabetes has been mostly 
unspecified, such a finding could be immensely beneficial to dissecting the nature of the 
disease and determining the primary responsible autoantigen. However, it has since been 
suggested that proinsulin may be the true primary autoantigen, whose T cell response 
occurs prior to that of G6PC2 [70]. Thus studies in mice showed that overexpression of 
proinsulin, but not G6PC2, in antigen-presenting cells abrogated the onset of diabetes 
[70]. This result was supported by studies showing that NOD mice expressing a form of 
proinsulin shown to be non-immunogenic did not develop type 1 diabetes [71], while 
deletion of G6pc2 from NOD mice had no effect on diabetes onset [72]. These data 
suggest that G6PC2 autoimmunity is not a critical step in the inception of type 1 diabetes 
in mice but do not rule out its potential role in disease advancement. 
 
Islet-Specific Expression and Transcriptional Regulation of G6PC2 
 Using immunofluorescent techniques, the expression pattern of G6pc2 was 
localized primarily to β-cells of the pancreatic islets, though a small subset of α-cells 
were also identified that appeared to express the gene [73]. As this expression profile 
places G6pc2 in a rather select family of islet-specific genes, much work has been 
focused on determining the molecular foundation of this specificity. Analysis of G6PC-
CAT fusion genes in β-cell lines implicated a portion of the proximal promoter, -306 to 
+3, as adequate to drive maximal expression of a reporter gene [74]. Further experiments 
were carried out to determine how this promoter region would respond in vivo. Though 
islet-specific expression of the transgene was initiated at the proper time in mice, its 
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promoter-driven activation was not sustained into the adult, implying a lack of critical 
promoter elements in the -306 to +3 region [73]. Continued exploration to elucidate other 
domains critical to transcription of G6pc2 is underway [75]. 
 Though expression of the transgene failed to persist in adult mice, the proximal (-
306/+3) sequence still comprises an islet-specific promoter. Work was thus begun to 
identify the transcription factors that bind this region, with the hope of discovering a 
novel factor critical for islet-specific gene expression. Putative factors were determined 
using bioinformatics software as well as in situ footprinting to search for binding sites of 
transcription factors in the proximal promoter [75, 76]. Binding of multiple factors, 
including Pdx-1, Pax-6, MafA, Foxa2, BETA-2, and USF, was confirmed in the 
insulinoma cell line βTC-3 via chromatin immunoprecipitation (ChIP) assay and 
mutational analysis [77-79]. These factors also regulate the transcriptional activation of 
the -306/+3 promoter, and are important for pancreatic expression of other genes, 
including insulin [80-82]. 
 
Splicing and Processing of pre-mRNA 
 Following gene activation by these and other transcription factors, the actual 
process of transcription generates pre-mRNA. Protein is derived from mRNA, thus pre-
mRNA must undergo splicing to reach this state. Pre-mRNA contains not only the 
sequences critical to proper protein formation in the form of exons but also introns that 
span the junctions between exons; G6PC2 contains 5 exons, separated by 4 introns of 
varying lengths [74]. Previously thought to be completely extraneous, introns have been 
shown to occasionally contain distinct coding regions for other proteins, enhancer 
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elements to promote activation of a gene, or noncoding RNA molecules [83]. Both 
introns and exons contain canonical splice sites that are recognized by components of the 
splicing machinery, termed the spliceosome. The splice site sequences utilized in the 
removal of the primary class of introns include the 5’ splice site, 3’ splice site, branch 
point element, and intronic polypyrimidine tract [84]. The spliceosome is comprised of 5 
RNA-protein complexes that are termed small nuclear ribonucleoproteins (snRNPs), 
which form distinct complexes throughout the course of splicing. The first complex 
formed (E) includes binding of the U1 snRNP to the 5’ splice site; U2AF binding to the 
polypyrimidine tract as well as the 3’ splice site through its 65 and 35 kDa subunits, 
respectively; and interaction of SF1 with the branch point sequence. In the second 
complex (A), ATP-dependent recruitment of U2 to the branch point sequence occurs via 
the 65 kDa subunit of U2AF. This is followed by binding of the U4/U6-U5 tri-snRNP to 
form the B complex, all of which are subsequently rearranged to form the catalytic 
complex (C). Upon rearrangement, base pairing between U4/U6 is disrupted to allow 
interaction of U6 with both the 5’ splice site and U2, displacing U1 and U4 in the 
process. It is at this point that U5, the most highly conserved snRNP, is finally able to 
bridge the 5’ and 3’ splice sites and the two transesterification reactions necessary for 
intron excision can occur. The intron is first detached from the upstream exon and 
reattached to the internal branch point sequence, forming an exon-intron lariat structure; 
this is followed closely by exon ligation and intron debranching. The detached intron 
lariat is then degraded and the components of the spliceosome recycled [85]. 
These splice sites are surprisingly less highly conserved in higher eukaryotes than 
lower eukaryotes such as Saccharomyces cerevisiae, and it is through this lack of 
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conservation that alternative splicing products arise [86, 87]. In many cases, the pre-
mRNA of a single gene can be spliced into multiple mRNA molecules each capable of 
forming discrete functional proteins; however, in other circumstances, the presence of 
another semi-conserved splice site can cause aberrant splicing. This form of alternative 
splicing can lead to formation of dysfunctional transcripts destined for nonsense mediated 
decay, or, in the situation that an aberrant splicing product does not contain a premature 
stop codon, potentially harmful protein isoforms [87]. 
 
Genetic Variation in G6PC2 and Human Disease Association 
 A recently developed powerful tool, the genome wide association (GWA) study, 
has become the primary technique for deciphering intricate disease states and the genes 
involved. The previously used linkage analysis method identified only rare genetic 
variants passed through families that contribute large effect sizes to the condition [88], 
while the alternate candidate gene approach only explored genes known to be associated 
with the diseased system [89]. The former lacked the power to elucidate variations in 
genes playing a smaller role in a disease while the latter excluded genes previously 
unknown to be involved. 
The sequencing of the human genome and affordable automated SNP genotyping 
encouraged the development of the GWA study methodology, a technique that enables 
the association of a disease or a disease characteristic with single nucleotide 
polymorphisms (SNPs) in ones genetic code. This in turn allows for a more unbiased 
identification of genes and gene variants that may contribute less drastically to a disease 
state. Due to the nature of the GWA study method and the low odds ratios accompanying 
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each variant, this technique may not yield definitive answers regarding SNPs and a 
disease state. Instead, a positive association of a SNP and a condition may imply a higher 
predisposition to said condition, increasing the potential for contribution by other genes 
or environmental influences to the state. Additionally, a common limitation of a GWA 
study is founded in the simple task of naming each polymorphism, usually for the gene 
with which it is most closely associated [89]. This can confound the understanding of 
SNP influences because a SNP contributed to a gene in close proximity may actually be 
acting in a distal manner on a completely disparate gene. A polymorphism may also be 
associated with a disease characteristic without being causative, instead being in high 
linkage disequilibrium (LD) with the true causative SNP [89]. Because of this, the result 
of a GWA study must be followed up by secondary experiments before confident 
association between a SNP and a phenotype can be made. Such is the foundation of the 
experiments in this thesis. 
As cases of diabetes rapidly increase worldwide, the importance of better 
understanding its genetic origins also increases, to which GWA studies have proved a 
significant boon. Through this experimental approach, several SNPs have been associated 
with type 2 diabetes while another subset of approximately 21 SNPs is associated with 
traits relevant to glycemia [89]. Studies designed to associate SNPs with variations in 
FPG by GWA study were performed in healthy individuals with normoglycemia [43, 90-
92]. It is from this group that a small number of SNPs found in proximity to G6PC2 were 
selected for further consideration; these are listed in Table 1.2. One of the strongest 
associations was found with SNP rs560887, located in the third intron of G6PC2. The 
presence of each minor T allele at this locus is associated with an approximate reduction  
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Table 1.2.  Loci identified in G6PC2 associated with variations in FPG 
 
Marker Location of SNP 
Allele 
(Major/Minor) 
Frequency of 
glucose raising 
allele 
Effect 
(mmol/L/allele) 
rs560887 Intron 3 C/T 0.69 0.071 
rs13431652 Distal promoter A/G 0.68 0.075 
rs573225 Proximal promoter A/G 0.66 0.073 
rs2232316 Proximal promoter G/A 0.12 0.05 
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in FPG of 1mg/dL [43]. This SNP has also been shown to associate with changes in 
hepatic glucose production and secretion of insulin after introduction of a glucose load 
[59-61]. The SNPs rs13431652, rs573225, and rs2232316, located in the G6PC2 
promoter, also associate with relatively similar variations in FPG as rs560887. 
While a change in FPG of 1mg/dL may seem rather trivial, various studies have 
indicated that this can play a significant role in ones health. One such study, based in a 
European population, determined that a rise in FPG from <90mg/dL to between 99 and 
108mg/dL is associated with an increased risk of 30% for cardiovascular associated 
mortality (CAM) [93]. The inverse was also demonstrated, such that another study of an 
Asian population illustrated a 25% reduction in the risk of CAM due to a decrease in FPG 
from 99mg/dL to 90mg/dL [94]. In addition to CAM, variations in FPG can also prove a 
risk factor for other disorders, including type 2 diabetes [95]. Such associations with a 
disease state would appear to solidify the importance of G6PC2 in regulating FPG and its 
correlating risk for CAM. 
 
Hypothesis on the Role of SNPs in G6PC2 Regulation 
 While numerous GWA studies have been performed to associate genetic variants 
with disease states, very few studies have extended this analysis to determine the 
functional effect of SNPs at a molecular level. The discovery of the G6PC2 SNPs within 
areas of high homology led to further examination of these regions and the formation of 
hypotheses to explain the association between these SNPs and variations in FPG. It was 
hypothesized that the SNPs within the promoter of G6PC2 associated with variations in 
FPG affect the binding of transcription factors critical to the activation of the gene. This 
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was tested through creation of fusion gene promoter constructs containing the various 
SNP alleles and subsequent transfection of cell culture lines to allow for reporter gene 
expression analyses, the data of which is included in Chapters III and IV. Additionally, 
the rs560887 SNP was theorized to affect constitutive splicing of G6PC2, causing 
increased formation of aberrantly spliced, nonfunctional isoforms. An in vitro splicing 
plasmid backbone was obtained from Dr. Thomas Cooper that allowed the splicing event 
and SNP in question to be analyzed. These results are described in detail in Chapter V. 
	   24 
CHAPTER II 
 
MATERIALS AND METHODS 
 
Fusion Gene Plasmid Construction 
rs573225 and rs13431652 
 The construction of mouse G6pc2-chloramphenicol acetyltransferase (CAT) 
fusion genes containing the wild-type promoter sequence from -306 to +3, or the same 
sequence with a site-directed mutation (SDM) of the Foxa2 binding site have been 
previously described. The construction of a human G6PC2-CAT fusion gene containing 
the wild-type promoter sequence from -324 to +3 has also been previously described. A 
three-step PCR strategy was used to introduce the rs573225-G allele or a two base pair 
mutation into the Foxa2 binding site in the human G6PC2 promoter within the context of 
the -324 to +3 promoter fragment. All promoter fragments were subcloned into the pGL3 
MOD and/or pGL4 MOD luciferase expression vectors. pGL3 MOD and pGL4 MOD 
were generated by replacing the polylinker in the pGL3-Basic or pGL4.16 vectors 
(Promega) with a polylinker containing the following restriction endonuclease 
recognition sites: KpnI, BamH1, HinDIII, XbaI, XhoI, and BglII. 
 An 8,574 base pair MfeI DNA restriction fragment extending from -8563 to +11 
relative to the human G6PC2 gene transcription start site was isolated from the 
previously described Pac 294 clone. This MfeI DNA fragment was ligated into the EcoRI 
site of the pGEM7 vector (Promega) and the resulting plasmid was designated 
G6PC2
	   25 
Pac 294 derived -8,563 to +11 G6PC2 promoter fragment were determined through DNA 
sequencing. Two additional G6PC2 subclones were then generated in pGEM7 so as to 
change the sequences of rs573225 and rs13431652 to their alternative alleles by site-
directed mutagenesis. One of these subclones, designated 
G6PC2Pac294SacShuttlepGEM7, was generated by isolating a SacI fragment from 
G6PC2Pac294MfepGEM7 that contained human G6PC2 promoter sequence from -8,563 
to -4,390. The second subclone, designated G6PC2Pac294XmaShuttlepGEM7, was 
generated by isolating an XmaI fragment from G6PC2Pac294MfepGEM7 that contained 
human G6PC2 promoter sequence from -2,803 to +11. The 
G6PC2Pac294SacShuttlepGEM7 plasmid was used as a template along with mutagenesis 
primers 5’-TGTCAGGCAGGCTGTGTCACTGGAGGGAAG-3’ and 5’-
CTTCCCTCCAGTGACACAGCCTGCCTGACA-3’ to convert rs13431652 at position -
4,405 from T to C and the G6PC2Pac294XmaShuttlepGEM7 plasmid was used as a 
template with mutagenesis primers 5’-
GGAAATGAACTGTACAAAAAATTTCAAGCAAACATGATCCAACTGTTC-3’ and 
5’-GAACAGTTGGATCATGTTTGCTTGAAATTTTTTGTACAGTTCATTTCC-3’ to 
convert rs573225 at position -259 from A to G. Mutagenesis was performed with these 
templates and primers using a QuikChange II Kit (Stratagene) as described by the 
manufacturer. 
 G6PC2-luciferase reporter plasmids, containing promoter sequence from -8,563 
to +11, were generated in the pGL3-Basic and pGL4.16 vectors (Promega) by a two-step 
process. In the initial cloning step, a SacI – HinDIII fragment was isolated from the 
G6PC2Pac294MfepGEM7 plasmid, using a SacI site in G6PC2 at -4,395 and a HinDIII 
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site within the pGEM7 vector, and ligated into the SacI – HinDIII digested pGL3-Basic 
and pGL4.16 vectors to generate fusion gene constructs that contain G6PC2 promoter 
sequence from -4,395 to +11. In the second cloning step a SacI fragment was isolated 
from the G6PC2Pac294SacShuttlepGEM7 plasmid and ligated into the SacI digested -
4,395 pGL3-Basic and pGL4.16 fusion gene plasmids to extend the G6PC2 promoter 
sequences from -4,395 to -8,563. 
 A SacI fragment from the G6PC2Pac294SacShuttlepGEM7 plasmid containing 
the alternate rs13431652 allele and an XmaI fragment from the 
G6PC2Pac294XmaShuttlepGEM7 plasmid with the alternate rs573225 allele were then 
exchanged with the corresponding SacI and/or XmaI fragments that contain the original 
Pac294 sequences to generate pGL3-Basic and pGL4.16 plasmids with the alternate SNP 
alleles within the context of the G6PC2 promoter region from -8,563 to +11. 
 
rs2232316 
 The originally isolated promoter contained the rs2232316-G and rs573225-A 
alleles [36]. The construction of human G6PC2-CAT [36] and human G6PC2-luciferase 
[96] fusion genes, both containing promoter sequence from -324 to +3, have been 
previously described. A three-step PCR strategy [78] was used to introduce the alternate 
rs2232316-A and/or rs573225-G alleles into the human G6PC2 promoter within the 
context of the -324 to +3 promoter fragment. 
 Human G6PC2 promoter fragments from -386 to +3 containing the alternate 
alleles of rs2232315 were generated by PCR using the following 5’ primers: 5’- 
CCCAAG(-386)CTTAAATTAAAATGCAGGGCTTTATGGGCTATTTGACATG-3’; 
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5’- CCCAAG(-386)CTTAAATTAAAATGCAGGACTTTATGGGCTATTTGACATG-
3’. HindIII sites used for cloning purposes are underlined, as are the rs2232315 alleles at 
-368. A ~9 kbp XhoI – XhoI fragment sub-cloned from PAC294 that contains the G6PC2 
promoter and exons 1-4 was used as the template [36]. 
 The 3’ primer was the same as that previously used to isolate the human G6PC2 
promoter sequence from -324 to +3 [36]: 5’- AACTGCAGTGCTCTGATTCCCACCG-
3’. A PstI site used for cloning purposes is underlined. This 3’ primer incorporates a 
single base pair change (italics) at position -1 in the human promoter that generates a PstI 
site such that the subsequent sub-cloning of the PCR fragments create fusion gene 
constructs with the same 3’ polylinker sequence between position +3 and the reporter 
gene as found in previously studied mouse and rat fusion gene constructs [36]. The PCR 
fragments were digested with HindIII and PstI and sub-cloned into HindIII – PstI 
digested pSP72 (Promega). The promoter fragments were then re-isolated from the 
pSP72 plasmid as HindIII – BamHI fragments and ligated into HindIII – BglII digested 
pCAT(An) expression vector. The promoter fragments were then re-isolated from the 
pCAT(An) plasmids as HindIII – XhoI fragments and sub-cloned into the pGL3 MOD 
luciferase expression vector [35]. pGL3 MOD was generated by replacing the polylinker 
in the pGL3-Basic vector (Promega) with a polylinker containing the following 
restriction endonuclease recognition sites: KpnI, BamHI, HindIII, XbaI, XhoI, and BglII. 
Promoter fragments generated by PCR were completely sequenced to ensure the absence 
of polymerase errors. All plasmid constructs were purified by centrifugation through 
cesium chloride gradients [97]. 
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rs560887, rs2232321, Exon 4 Splice Junction, and rs35259259 
 The RHCglo minigene vector was a generous gift from Dr. T. Cooper (Baylor 
College of Medicine). A G6PC2 fragment containing exon 4 and ~300bp of 5’ and 3’ 
intronic sequence was isolated using PCR with the PAC 299 plasmid as the template in 
conjunction with the following primers: 5’-
ACGCGTCGACGGTTCATTCTTGATCATTCTGG-3’ and 5’- 
GCTCTAGACTCAGAGTCATTAAGTTCCCTC-3’ (SalI and XbaI cloning sites 
underlined). The PCR fragment was digested with SalI and XbaI and ligated into the SalI-
XbaI digested RHCglo vector. The alternate rs560887-T allele was introduced into the 
resulting plasmid using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA) in conjunction with the following primers: 5’- 
GATCCAGTTTCTTTGCTTTTTATGCTTGTATCTATTCTTCCATCG-3’ and 5’- 
CGATGGAAGAATAGATACAAGCATAAAAAGCAAAGAAACTGGATC-3’ 
(mutated base underlined). The alternate rs2232321-A allele and the consensus exon 4 5’ 
splice junction were then introduced into the resulting plasmid containing the rs560887-T 
allele using the following primers: rs2232321: 5’- 
GTGATCCAGTTTCTTTGCTTTTTATACTTGTATCTATTCTTCCATC-3’ and 5’- 
GATGGAAGAATAGATACAAGTATAAAAAGCAAAGAAACTGGATCAC-3'; exon 
4 junction: 5'-TATCTATTCTTCCATCGTAGGCTGACCTGGTCATTTCTTTG-3' and 
5'-CAAAGAAATGACCAGGTCAGCCTACGATGGAAGAATAGATA-3' (mutated 
bases underlined). A G6PC2 fragment containing ~1300bp of exon 5 and ~300bp of 5’ 
intronic sequence was isolated using PCR with the PAC 299 plasmid as the template in 
conjunction with the following primers: 5'-
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ACGCGTCGACCAAAGGCTAATTGGCTATGGC-3' and 5'-
GCTCTAGACAAATATAGTAAGAAGCTGG-3' (Sal I and Xba I cloning sites 
underlined). The PCR fragment was digested with SalI and XbaI and ligated into the SalI-
XbaI digested RHCglo vector (Fig. 2.1). The alternate rs35259259 allele was introduced 
into the resulting plasmid using the QuikChange II Site-Directed Mutagenesis Kit in 
conjunction with the following primers: 5'-TCTTTCCAATCCTCAG-
CATGCTGGTGGCAGAG-3' and 5'-CTCTGCCACCAGCATG-
CTGAGGATTGGAAAGA-3' (deleted bases underlined). 
 
Cell Culture 
 All cell lines, including the pancreatic islet-derived cell lines βTC-3, Min6, 
Hamster insulinoma tumor (HIT), and the 832/13 sub-clone of INS-1, as well as HeLa, 
were passaged as subconfluent cultures (150 cm2 flasks) in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. 
βTC-3 and Min6 cultures were also supplemented with 10% (vol/vol) fetal bovine serum, 
HIT cultures with 2.5% (vol/vol) fetal bovine serum and 15% (vol/vol) horse serum, and 
HeLa cultures with 10% (vol/vol) calf serum. 
 
Transient Transfection 
 Cells were grown to approximately 70% confluence and were replated the day 
before use into 35 mm-diameter six-well dishes (one 150 cm2 flask to 10 dishes). 
Attached cells were briefly incubated for 10 min in Opti-MEM reduced serum medium 
(GibcoBRL) before transfection using the lipofectamine reagent (GibcoBRL), per the 
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manufacturer’s instructions. Separately, 2 μg of experimental plasmid DNA and 0.5 μg 
control plasmid DNA (Renilla (Promega) and firefly luciferase for the luciferase and 
CAT assays, respectively) were mixed with 100 μL Opti-MEM reduced serum medium. 
A solution containing 12.5 μL lipofectamine and 100 μL Opti-MEM reduced serum 
medium was then added dropwise to the DNA solution and incubated for 30 min. This 
DNA/lipofectamine mixture was then diluted with 800 μL of Opti-MEM reduced serum 
medium, and the resulting solution was added to the cells, which were returned to 37°C 
in a humidified 5% CO2/95% air atmosphere in a Nuaire cell culture incubator. Following 
incubation for between 4 and 6 hours, the transfection medium was aspirated and 
replaced with the standard culture media prior to a final incubation for 18-20 hours. 
 
CAT and Luciferase Assays 
 Transfected cells were harvested by trypsin digestion, suspended in 1X passive 
lysis buffer (Promega), and exposed to two cycles of freeze/thawing. 
CAT Assays 
Cell lysates for CAT assays were heated for 10 min at 65°C and cellular debris 
removed by centrifugation. From the resulting supernatant, a 100 μL aliquot was 
incubated in a final volume of 250 μL containing (at final concentrations) 200mM 
Tris HCl (pH 7.8), 6mM MgCl2, 75mM KCl, 0.4mM coenzyme A, 3mM ATP, 1mM 
chloramphenicol, 0.03 U of acetyl coenzyme A synthetase, and 0.34mM [3H]acetate (0.5 
Ci/mmol). This mixture was incubated for 2 h at 37°C, extracted with benzene, and 
transferred into scintillation vials. After removal of the benzene by evaporation, the 
[3H]acetate incorporated into chloramphenicol was quantified by scintillation 
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spectroscopy. The counts per minute in a lysate-free blank were subtracted, and CAT 
activity was corrected for variations in protein concentration of the cell lysates, as 
measured by the Pierce bicinchoninic acid assay. 
Luciferase Assays 
After two cycles of freeze/thawing, firefly and Renilla luciferase activity were 
assayed sequentially in 10 μL of lysate using the dual luciferase assay kit (Promega). The 
activity of the G6PC2 promoter was expressed as the ratio of the firefly/Renilla luciferase 
activities and is thus corrected for differences in transfection efficiency and cell viability. 
 
Gel Retardation Assays 
Labeled Probes 
 Sense and anti-sense oligonucleotides representing wild-type or mutant Foxa 
binding sites or the rs573225 variants were synthesized with BamHI compatible ends. 
Oligonucleotides representing the rs13431652 variants of the NF-Y binding site were 
synthesized with HinDIII compatible ends. Oligonucleotides were subsequently gel 
purified, annealed, and labeled with [α32P]dATP using the Klenow fragment of 
Escherichia coli DNA Polymerase I to a specific activity of ~2.5 μCi/pmol. 
Nuclear Extract Preparation 
 The preparation of βTC-3 and H4IIE nuclear extracts through extraction of nuclei 
with 800mmol/L NaCl (designated high salt) was as previously described [78]. The 
preparation of rat liver nuclear extract was also performed as previously described. 
Binding Assays 
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 Approximately 14 fmol of radiolabeled probe (~50,000 cpm) was incubated with 
the indicated nuclear extract in a final 20 μL reaction volume. Foxa2 binding reactions 
contained 1.0 μg βTC-3, 2.0 μg liver, or 2.0 μg H4IIE nuclear extract, 20mmol/L Hepes 
pH 7.9, 0.1mmol/L EDTA, 0.1mmol/L EGTA, 10% glycerol (v/v), 1mmol/L 
dithiothreitol, 1 μg poly(dI-dC) poly(dI-dC), and 50mmol/L KCl. After incubation at 
room temperature for 20 minutes, samples were loaded onto a 6% polyacrylamide gel 
containing 1X TGE (25mmol/L Tris Base, 190mmol/L glycine, 1mmol/L EDTA) and 
2.5% (v/v) glycerol. Samples were electrophoresed for 1.5 h at 150V in 1X TGE buffer 
before the gel was dried and then exposed to Kodak XB film with intensifying screens. 
Competition and supershift experiments were performed as previously described [78]. 
For supershift experiments, antisera raised against Foxa2 (HNF-3β) (sc-65540x) and NF-
Y (sc-17753x) were obtained from Santa Cruz Biotechnology. A Pharos FX Plus 
Molecular Imager in conjunction with Imaging Screen and Cassette K and the Quantity 
One program (Bio-Rad) were used to quantitate 32P associated with protein-DNA 
complexes. 
 
Minigene Splicing Analyses 
 Human cervix-derived HeLa cells were grown in Dulbecco’s modified Eagle’s 
medium containing 10% (vol/vol) bovine serum. Cells were transiently transfected with 2 
μg of the plasmids described above using lipofectamine as previously described. 18 hr 
following transfection cells were harvested by trypsin digestion (Bischof, 2001) and 
resuspended in Denaturation Solution (Ambion RNAqueous Kit) prior to RNA isolation 
according to the manufacturers’ instructions. RNA (10 μg) was treated with Turbo-
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DNase (Ambion Turbo DNA-free) per the manufacturers’ instructions for 30 min at 37°C 
and then overnight with Dpn I to digest plasmid DNA. Reverse transcription (RT) 
reactions were carried out using the Bio-Rad iScript cDNA Synthesis Kit: 4 μL buffer 
mix, 5 μL treated RNA (1 μg), 10 μL water, and 1 μL reverse transcriptase were 
incubated at 25°C for 5 min, 42°C for 30 min, and then 85°C for 5 min. PCR reactions 
(final volume 100 μL) were performed using 0.1 μL of the RT reaction product with 5 U 
Taq polymerase (Applied Biosystems), 10 μL 10X PCR Buffer II (Applied Biosystems), 
1.5 μM MgCl2 (Applied Biosystems), 5 μL DMSO, 2 μCi [α-32P]-dATP (Perkin Elmer), 
200 nM dNTPs (200 nM each), and 100 nM of the following primers: 5’- 
CCCAAGCTTCATTCACCACATTGGTGTGC-3’ and 5’- 
CCGCTCGAGGGGCTTTGCAGCAACAGTAAC-3’ (HinD III and Xho I cloning sites 
underlined). Reaction conditions were 24 cycles at 95°C for 1 min, 55°C for 1 min, and 
72°C for 1 min, followed by one cycle at 72°C for 5 min. Reactions products were loaded 
on a 6% polyacrylamide gel containing 1X TGE (25 mM Tris Base, 190 mM glycine, 1 
mM EDTA) and 2.5% (v/v) glycerol. Samples were electrophoresed for 1.5 hrs at 150V 
in 1X TGE buffer before the gel was dried and exposed to Kodak XB film with 
intensifying screens. For data quantitation, dried gels were exposed to a Bio-Rad Imaging 
Screen K overnight, which was then scanned in a Bio-Rad Molecular Imager FX System. 
PCR bands were quantitated using the “Volume Rectangle Tool” and “Mean Value” 
quantifier with the “Volume Analysis Report: of the Quantity One program. Background 
was measured with a separate volume and subtracted. To confirm the identity of splice 
junction reaction products were digested with HinD III and Xho I and ligated into HinD 
III – Xho I digested pGEM7 (Promega) for DNA sequencing. 
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Statistical Analysis 
 The transfection data were analyzed for differences from the control values, as 
specified in the figure legends. Statistical comparisons were calculated using an unpaired 
Student t test. The level of significance was P < 0.05 (two-sided test).  
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CHAPTER III 
 
FUNCTIONAL DATA SUPPORT A POTENTIAL ROLE FOR rs13431652 AS A 
CAUSATIVE G6PC2 SNP CONTRIBUTING TO VARIATION IN FPG 
 
 
Introduction 
 The genetic association of multiple allelic variants of G6PC2 with variations in 
FPG necessitates analysis of the potential functional contribution of each SNP. The 
intronic SNP rs560887 shows high LD (>0.80) with two promoter SNPs, rs13431652 and 
rs573225, according to data from HapMap phase III (r2 = 0.88 and r2 = 0.96, 
respectively). Their contributions to FPG, however, have not yet been examined. To 
ascertain whether these SNPs potentially affect glucose homeostasis, further genetic 
association analyses were first carried out by our collaborators Nabila Bouatia-Naji and 
Philippe Froguel. Following the demonstration of independent genetic linkage between 
rs13431652 and rs573225 and FPG, a biochemical approach was taken to evaluate the 
effects of these promoter variants on transcription factor binding and promoter activity. 
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Results 
 
Association of promoter variants of G6PC2 with FPG 
 Only two common SNPs (minor allele frequency > 0.05), namely rs13431652 and 
rs573225, are reported to be in high linkage disequilibrium (LD) with the previously 
identified intronic G6PC2 SNP rs560887 (r2 > 0.80, according to HapMap data [release 
XX]). rs13431652 is located in the distal G6PC2 promoter, at -4405 relative to the 
transcription start site, whereas rs573225 is located in the proximal promoter at -259. We 
have assesse the effect of these two G6PC2 promoter variants on FPG, adjusted for age, 
sex, and BMI in 9532 NG Europeans from four independent populations. In the meta-
analyses, we show strong associations of both rs13431652 (β = 0.075, P = 3.6x10-35) and 
rs573225 (β = 0.073, P = 3.6x10-34) with FPG, in similar magnitude to that for rs560887 
(β = 0.075, P = 3.6x10-35) (Table 3.1). Conditioned regression model analyses to assess 
the independency of the three SNPs studied turn out to be noninformative (data not 
shown), as these analyses include a high variance inflation factor because of high LD that 
we observed between the SNPs in our populations. 
 To compensate for this limited analytical situation, we analyzed the association of 
FPG with multiple haplotypes of the promoter variants and rs560887, specifically 
individual contributions of each variant and contributions when variants were analyzed in 
pairs and when we constrained the effect of rs560887 to be null. Because of the LD 
discrepancies between populations, these haplotype analyses were conducted in the four 
poopulations separately. In DESIR, we found that rs560887 is significantly contributing 
to the haplotype association in combination with rs13431652 (P = 7.58x10-5) and  
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cassette family B 11) encodes the major bile salt export
pump and is expressed predominantly in the liver (29) and
was hypothesized to potentially drive the association with
FPG observed at this locus (12). We found a significant
association between rs853789 and FPG (! " #0.062, P "
1.1 $ 10#25, supplementary Table 4). However, when we
include either rs560887, rs13431652, or rs573225 in a
regression conditional model that includes rs853789, age,
sex, BMI, and cohort, the effect of rs853789 is highly
reduced (supplementary Table 4), whereas rs13431652
(P" 1.2$ 10#10), rs573225 (P" 1.8$ 10#9), and rs560887
(P " 1.3 $ 10#7) remain strongly associated with FPG
(supplementary Table 5). These findings were confirmed
by the haplotype analyses that did not support a frank,
independent contribution of rs853789 to the association in
any of the cohorts studied (supplementary Table 3). These
genetic data suggest that in our populations, the ABCB11
rs853789 effect on FPG is driven mainly by G6PC2 varia-
tion through moderate LD, estimated between 0.42 and
0.78, depending on the population studied (supplementary
Table 5).
Expression analyses. Using quantitative real time PCR
we confirmed that the expression of G6PC2 is restricted to
pancreatic tissues, including whole pancreas, islets and
sorted !-cells, in humans (supplementary Fig. 1A). Similar
results were previously reported through RNA blotting
analyses of mouse (2,9) and human (3) RNA. In a limited
sample (N " 24) in which pancreatic islet cDNAs and
corresponding genomic DNAs were available, we found no
significant correlation between the alleles of rs13431652-A,
rs573225-A, or rs560887-G, that are associated with high
FPG and G6PC2 gene expression (supplementary Fig. 1B).
Because of the limited sample sizes in the genetic and
expression analyses, it was not possible to identify a
causative variant among rs13431652, rs573225, and
rs560887. We therefore decided to take a biochemical
approach to assess the ability of the promoter variants to
affect transcription factor binding and G6PC2 promoter
activity and, hence, their ability to alter FPG levels.
NF-Y binds to the G6PC2 promoter in vitro. The
G6PC2 promoter region that encompasses rs13431652 was
analyzed using MatInspector sequence analysis software
(30) with the goal of identifying a cis-acting element
whose binding of its cognate trans-acting factor was likely
to be affected by the alternate rs13431652 alleles. This
analysis identified a CCAAT box (Fig. 1A), an element
known to bind multiple transcription factors, including
NF-Y (31,32). The SNP changes the sequence CCAaT to
CCAgT.
Gel retardation assays were used to investigate whether
NF-Y can bind to this G6PC2 promoter region in vitro.
When a labeled double-stranded oligonucleotide, desig-
nated rs13431652-A, representing the G6PC2 promoter
sequence from #4,425 to #4,392 and the rs13431652-A
allele (Fig. 1A), was incubated with nuclear extract pre-
pared from !TC-3 cells a single protein-DNA complex was
detected (Fig. 1B).
To identify the factor present in this complex, a gel
retardation assay was performed in which !TC-3 cell
nuclear extract was preincubated with antisera specific for
NF-Y or, as a control, USF-2. As can be seen in Fig. 1B,
addition of antibodies recognizing NF-Y resulted in a clear
supershift in the migration of the complex, whereas the
addition of antibodies recognizing USF-2 had no effect.
This result strongly suggests that the complex represents
NF-Y binding.TA
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rs573225 (P = 0.015). We also observed a significant contribution of rs13431652 (P = 
4.09x10-7) and rs573225 (P = 1.21x10-8) to the haplotype associations, supporting 
independent effects of both promoter variants to the global association of the haplotype in 
combination with rs560887. In contrast, distinct results were obtained in the remaining 
cohorts in which we found that both promoter and intronic variants are not independently 
contributing to the haplotype associations, suggesting that promoter and intronic variants 
are indispensable to the two by two haplotype associations, with a modestly more 
significant contribution of rs560887 (P = 0.006 against rs13431652 and P = 0.07 against 
rs573225) in the NFBC 1986 cohort. We speculate that these distinct results in some way 
reflect the differences in LD within the different cohorts. Despite these differences, 
haplotype analyses support a substantial role of promoter variants to the association 
signal with FPG, and do not discard the contribution of rs560887. 
 We have also assessed the effect of the intronic variant rs853789 located in the 
19th intron of ABCB11, one of two SNPs, along with rs560887, that were reported by 
Chen et al. [91] to be associated with FPG. ABCB11 (ATP-binding cassette family B 11) 
encodes the major bile salt export pump and is expressed predominantly in the liver [98] 
and was hypothesized to potentially drive the association with FPG observed at this locus 
[91]. We found a significant association between rs853789 and FPG (β = -0.062, P = 
1.1x10-25). However, when we include either rs560887, rs13431652, or rs573225 in a 
regression conditional model that includes rs853789, age, sex, BMI, and cohort, the 
effect of rs853789 is highly reduced, whereas rs13431652 (P = 1.2x10-10), rs573225 (P = 
1.8x10-9), and rs560887 (P = 1.3x10-7) remain strongly associated with FPG. These 
findings were confirmed by the haplotype analyses that did not support a frank, 
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independent contribution of rs853789 to the association in any of the cohorts studied. 
These genetic data suggest that in our populations, the ABCB11 rs853789 effect on FPG 
is driven mainly by G6PC2 variation through moderate LD, estimated between 0.42 and 
0.78, depending on the population studied. 
 
Expression Analyses 
 The expression profile of G6PC2 was confirmed by quantitative real time PCR as 
restricted to pancreatic tissues. In humans this includes whole pancreas, islets, and β cells 
(Fig. 3.1A). These data had previously been reported for mouse [32, 43] and human [36] 
tissue through RNA blotting. No significant association of the minor alleles of 
rs13431652, rs573225, or rs560887 with high FPG and G6PC2 gene expression were 
found (Fig. 3.1B). This was based on a small number of samples (N = 24) of pancreatic 
islet cDNA whose corresponding genomic DNA was available. Because of this, and the 
small sample size of the genetic analyses, a causative variant among the three SNPs was 
not determined. 
 
Transcription factor binding at rs13431652 in vitro 
 To identify a cis-acting element whose corresponding binding factor was likely to 
be affected by allelic variation at rs13431652, MatInspector sequence analysis software 
was employed [99]. By analyzing the G6PC2 promoter region encompassing this SNP, a 
CCAAT box was found (Fig. 3.2A). This DNA-binding element is known to bind several 
different transcription factors, including NF-Y [100, 101], and its sequence changes from 
CCAaT to CCAgT with the minor allele of rs13431652. 
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Figure 3.1.  Analysis of G6PC2 gene expression 
(A) G6PC2 expression was analyzed in human tissues by real-time PCR and data 
normalized according to expression levels of the house keeping gene POLR2A. (B) 
G6PC2 expression was analyzed in pancreatic islets, relative to G6PC2 genotypes, by 
real-time PCR and data is normalized according to expression levels of the house keeping 
gene POLR2A.  
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Supplementary Figure 1. Analysis of G6PC2 gene expression. G6PC2 expression was 
analyzed in human tissues (Panel A) and in pancreatic islets, relative to G6PC2 genotypes (Panel 
B). G6PC2 expression was analyzed by real-time PCR and data is normalised according to 
expression levels of the house keeping gene POLR2A.  
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Figure 3.2.  Binding of the -4425/-4392 promoter region of G6PC2 by NF-Y in vitro 
(A) The sense strand sequences of the oligonucleotides used in gel retardation assays are 
shown. SNP base pairs are shown in bold lower case letters. The consensus NF-Y binding 
motif, CCAAT, is taken from Quandt et al. (B) βTC-3 nuclear extract was incubated in 
the absence or presence of the indicated anti-serum for 10 min on ice. A labeled 
oligonucleotide representing the -4425/-4392 G6PC2 promoter region and containing the 
rs13431652-A allele (rs13431652-A; Panel A) was then added and incubation continued 
for 20 min at room temperature. Protein binding was then analyzed using the gel 
retardation assay as described in Chapter II. In the representative autoradiograph shown, 
only the retarded complexes are visible and not the free probe, which was present in 
excess. 
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Binding analyses of NF-Y to the G6PC2 promoter in vitro were carried out by gel 
retardation assay. A radioactively labeled double-stranded oligonucleotide, designated 
rs13431652-A, represented the G6PC2 promoter sequence from -4425 to -4392 and 
included the rs13431652-A allele. Following incubation of rs13431652-A with nuclear 
extract prepared from βTC-3 cells, a single protein-DNA complex was detected by 
phosphorimaging (Fig. 3.2B). This binding factor was identified by gel retardation assay 
in which the βTC-3 cell nuclear extract was pre-incubated with control or experimental 
antisera for USF-2 or NF-Y, respectively. Addition of the antibodies specific for NF-Y 
resulted in a distinct supershift in the migration of the complex, while pre-incubation with 
antisera for USF-2 did not affect the complex migration (Fig. 3.2B). These results 
strongly suggest association of NF-Y in this complex. 
 Comparison of the affinity of NF-Y binding to the variants of rs13431652 in the 
G6PC2 promoter was carried out utilizing gel retardation competition experiments, in 
which an increasing molar excess of unlabeled DNA was included with the labeled major 
allele oligonucleotide—in this case rs13431652-A. It can be seen that the rs13431652-A 
oligonucleotide more effectively competed for the formation of the NF-Y-DNA complex 
than the rs13431652-G oligonucleotide (Fig. 3.3A). Quantification of this result from 
multiple experiments elucidated that the rs13431652-A oligonucleotide is bound by NF-
Y with approximately five fold higher affinity (Fig. 3.3B). In contrast to the competition 
experiment data, however, direct analysis of NF-Y binding to the A and G alleles of 
rs13431652 using separate oligonucleotide probes labeled with equal specific activity 
indicated a greater difference in NF-Y binding affinity (Fig. 3.3C). This incongruity, 
observed prior in studies on FOXO1 binding [102], is hypothesized to arise when the  
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Figure 3.3.  Comparison of the affinity of NF-Y binding to the rs13431652-A and 
rs13431652-G variants of the G6PC2 NF-Y binding site in vitro 
(A) The labeled rs13431652-A oligonucleotide (Fig. 3.1A) was incubated in the absence 
or presence of the indicated molar excess of the unlabeled human rs13431652-A or 
rs13431652-G oligonucleotide competitors (Fig. 3.1A) before the addition of βTC-3 cell 
nuclear extract. Protein binding was then analyzed using the gel retardation assay as 
described in Chapter II. In the representative autoradiograph shown, only the retarded 
complexes are visible and not the free probe, which was present in excess. (B) Protein 
binding was quantified by using a Packard Instant Imager to count 32P associated with the 
retarded complex. The data represent the mean ± S.E.M. of three experiments. (C) The 
labeled rs13431652-A and rs13431652-G oligonucleotides (Fig. 3.1A) were incubated 
with βTC-3 cell nuclear extract, and protein binding was analyzed using the gel 
retardation assay as described in Chapter II. In the representative autoradiograph shown, 
only the retarded complexes are visible and not the free probe, which was present in 
excess. 
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rates of association and dissociation of a factor interacting with DNA are increased 
concurrently. Such an effect would yield a limited variation in KD [103]; however, a 
significant difference in the dissociation of the protein-DNA complex upon separation of 
bound and free probe during electrophoresis would result. 
 
Alteration of G6PC2 fusion gene expression by rs13431652 
 The functional significance of altered NF-Y binding on human G6PC2 promoter 
activity was next investigated. NF-Y can function as either an activator or repressor such 
that the effect of NF-Y on gene transcription is context dependent [104]. Fusion genes 
containing each of the alleles of rs13431652, generated in the context of the -8563 to +11 
G6PC2 promoter region, were analyzed by transient transfection of βTC-3 cells. Figure 
3.4 shows that the rs13431652-G allele was associated with an approximately 25% 
decrease in promoter activity in comparison to that observed with the rs13431652-A 
allele. Figure 3.5 shows that this difference was only observed when the G6PC2 
promoter was analyzed in the context of the pGL4 but not the pGL3 vector; the former is 
an improved vector that lacks multiple transcription factor binding sites in the plasmid 
backbone and luciferase gene that are known to occasionally give rise to spurious data 
[79]. These results indicate that NF-Y acts as an activator in the context of the G6PC2 
promoter. More importantly, these data are consistent with the reduced FPG observed in 
G6pc2 knockout mice [55] in that the rs13431652-A allele is associated with both 
elevated FPG and G6PC2 promoter activity. As such, these functional data support a 
potential role for rs13431652 as a SNP linking G6PC2 to variations in FPG. 
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Figure 3.4.  Decreased G6PC2 promoter activity associated with the human G6PC2 
rs13431652-G allele relative to the rs13431652-A allele 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL4 
MOD vector (2 μg) and an expression vector encoding Renilla luciferase (0.5 μg). The 
G6PC2-luciferase fusion genes represented the rs13431652-A or rs13431652-G alleles 
present in the context of the human G6PC2 promoter sequence located between -8563 
and +11. After transfection, cells were incubated for 18-20 h in serum-containing 
medium. The cells were then harvested, and firefly and Renilla luciferase activity were 
assayed as described in Chapter II. Results are presented as the ratio of firefly:Renilla 
luciferase activity, expressed as a percentage relative to the value obtained with the 
rs13431652-A allele, and represent the mean of 12 experiments ± S.E.M., each using an 
independent preparation of each fusion gene plasmid, assayed in triplicate. *P < 0.05 vs. 
rs13431652-A allele. 
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Figure 3.5.  Decreased G6PC2 promoter activity associated with the human G6PC2 
rs13431652-G allele relative to the rs13431652-A allele in pGL4 but not pGL3 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL3 
MOD (Panel A) or pGL4 MOD (Panel B) vectors (2 μg) and an expression vector 
encoding Renilla luciferase (0.5 μg). The G6PC2-luciferase fusion genes represented the 
rs13431652-A or rs13431652-G alleles present in the context of the human G6PC2 
promoter sequence located between -8563 and +11. After transfection, cells were 
incubated for 18-20 h in serum-containing medium. The cells were then harvested, and 
firefly and Renilla luciferase activity were assayed as described in Chapter II. Results are 
presented as the ratio of firefly:Renilla luciferase activity, expressed as a percentage 
relative to the value obtained with the rs13431652-A allele, and represent the mean of 
three experiments ± S.E.M., each using an independent preparation of each fusion gene 
plasmid, assayed in triplicate. *P < 0.05 vs. rs13431652-A allele.  
 
©2010 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0389/DC1 
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Supplementary Figure 2. The human G6PC2 rs13431652-G allele is associated with 
decreased G6PC2 promoter activity relative to the rs13431652-A allele in the context of the 
pGL4 but not the pGL3 vector. 
 βTC-3 cells were transiently co-transfected, as described in Research Design and 
Methods, using a lipofectamine solution containing human G6PC2-luciferase fusion genes in the 
pGL3 MOD (Panel A) or pGL4 MOD (Panel B) vectors (2 µg) and an expression vector 
encoding Renilla luciferase (0.5 µg). The G6PC2-luciferase fusion genes represented the 
rs13431652-A or -G alleles present in the context of the human G6PC2 promoter sequence 
located between -8563 and +11. Following transfection, cells were incubated for 18-20 hr in 
serum-containing medium. The cells were then harvested and firefly and Renilla luciferase 
activity was assayed as described in Research Design and Methods. Results are presented as the 
ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the value obtained 
with the rs13431652-A allele, and represent the mean of 9-12 experiments ± S.E.M., each using 
an independent preparation of each fusion gene plasmid, assayed in triplicate. *, p < 0.05 versus 
rs13431652-A allele. 
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Supplementary Figure 3. Comparison of Foxa2 binding to the labeled human G6PC2 -265/-
246 and mouse G6pc2 -247/-228 promoter regions in vitro. 
 Labeled oligonucleotides representing the wild-type (WT) human G6PC2 -265/-246 or 
mouse G6pc2 -247/-228 promoter regions wer  incubate  in the absence or presence of a 100-
fold molar excess of the indicated unlabeled WT or utant (MUT) competitors (Suppl. Table 6). 
βTC-3 nuclear extract was then added and protein binding was analyzed using the gel retardation 
assay as described in Research Design and Methods. In the representative audioradiograph 
shown, only the retarded complexes are visible and not the free probe, which was present in 
excess. The two major complex s tected represent Foxa2 (A2) and non-specific (NS) binding 
(4). 
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Transcription factor binding at rs573225 in vitro 
 The G6PC2 promoter region that encompasses rs573225 is highly conserved in 
the mouse G6pc2 promoter [36]. This conserved region was recently characterized in the 
context of the mouse G6pc2 promoter, showing that it contains a Foxa2 binding site [79]. 
In addition, it was demonstrated by chromatin immunoprecipitation assay (ChIP) that 
Foxa2 binds the endogenous G6pc2 promoter in mouse βTC-3 cells in situ. Figure 3.6 
shows that this region of the human G6PC2 promoter also binds Foxa2 in vitro. When 
labeled double-stranded oligonucleotides, designated rs573225-A and -G (Fig. 3.6A), 
representing the G6PC2 promoter sequence from -265 and -246 and the rs573225-A and 
-G alleles, respectively, were incubated with rat liver nuclear extract a single major 
complex, designed A2, was detected with both alleles (Fig. 3.6B). When rat liver nuclear 
extract was pre-incubated with antisera specific for Foxa2 a clear supershift in the 
migration of complex A2 was observed (Fig. 3.6B), strongly suggesting that this complex 
represents Foxa2 binding. This experiment was performed using rat liver nuclear extract, 
because, like pancreatic islets [105], it contains both Foxa1 and Foxa2 [106]. In contrast, 
βTC-3 cells only express Foxa2 [79]. The results indicate that rs573225 does not 
differentially affect binding of these related factors; instead, both alleles strongly bind 
Foxa2. 
 Gel retardation competition experiments, in which a varying molar excess of 
unlabeled DNA was included with the labeled rs573225-A probe, were used to compare 
the affinity of Foxa binding to the rs573225 variants of the G6PC2 Foxa binding site. 
Figure 3.7A shows that, when using rat liver nuclear extract, both the rs573225-A and -G 
oligonucleotides competed equally effectively for the formation of the Foxa2-DNA  
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Figure 3.6.  Binding of the -265/-246 promoter region of G6PC2 by Foxa2 in vitro 
(A) The sense strand sequences of the oligonucleotides used in gel retardation assays are 
shown. SNP base pairs are shown in bold lower case letters. The consensus Foxa binding 
motif, (A/G)A(G/A)(C/T)(C/A)AA(C/T)A(T/A)T(T/G/C), is taken from Overdier et al. 
(B) Liver nuclear extract was incubated in the absence (None) or presence of the 
indicated anti-serum for 10 min on ice. Labeled oligonucleotides representing the -265/-
246 G6PC2 promoter region and containing the rs573225-A or rs573225-G alleles 
(rs573225-A or rs573225-G; panel A) were then added and incubation continued for 20 
min at room temperature. Protein binding was then analyzed using the gel retardation 
assay as described in Chapter II. In the representative autoradiograph shown, only the 
retarded complexes are visible and not the free probe, which was present in excess. A 
single major complex was detected (A2) that represents Foxa2 binding. The arrow 
indicates a supershifted complex. 
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Figure 3.7.  Comparison of the affinity of Foxa binding to the rs573225-A and 
rs573225-G variants of the G6PC2 Foxa binding site in vitro 
(A) The labeled rs573225-A oligonucleotides (Fig. 3.4A) was incubated in the absence or 
presence of the indicated molar excess of the unlabeled human rs573225-A or rs573225-
G oligonucleotide competitors (Fig. 3.4A) before the addition of βTC-3 cell or rat liver 
nuclear extract. Protein binding was then analyzed using the gel retardation assay as 
described in Chapter II. In the representative autoradiograph shown, only the retarded 
complexes are visible and not the free probe, which was present in excess. With βTC-3 
nuclear extract, complex A2 represents Foxa2 binding, and complex NS represents 
nonspecific binding (Martin 2008). With liver nuclear extract, complex A2 represents 
Foxa2 binding (O’Brien 1995 Hepatic nuclear factor 3- and hormone-regulated 
expression…). (B) Protein binding in experiments using liver nuclear extract was 
quantified by using a Packard Instant Imager to count 32P associated with the retarded 
complex. The data represents the mean ± S.E.M. of three experiments. (C) The labeled 
rs573225-A and rs573225-G oligonucleotides (Fig. 3.4A) were incubated with either 
liver or H4IIE nuclear extract, and protein binding was analyzed using the gel retardation 
assay as described in Chapter II. In the representative autoradiograph shown, only the 
retarded complexes are visible and not the free probe, which was present in excess. NS, 
nonspecific. 
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complex. Quantitation of the results of several experiments confirmed that Foxa2 binds 
the rs573225-A and -G oligonucleotides with equal affinity (Fig. 3.7B). Identical results 
were obtained using mouse βTC-3 cell nuclear extract (Fig. 3.7A). It has previously been 
shown that the two complexes detected using βTC-3 cell nuclear extract represent the 
binding of Foxa2 (A2) and an unknown factor that either represents a non-specific (NS) 
interaction or binding to another region of the probe [79]. 
 Interestingly, in contrast to the competition experiment data (Fig. 3.7A & B), the 
direct analysis of Foxa2 binding to the rs573225-A and -G oligonucleotides probes 
labeled with the identical specific activity showed that Foxa2 binds with slightly higher 
affinity to the rs573225-A allele (Fig. 3.6B & 3.7C). The identical observation was made 
using rat liver and rat H4IIE hepatoma cell nuclear extract (Fig. 3.7C). As explained 
above in the analysis of NF-Y binding (Fig. 3.3C), this suggests that rs573225 alters the 
association and dissociation rates of Foxa2 binding without affecting binding affinity. 
 
Alteration of G6PC2 fusion gene expression by rs573225 
 We next investigated the functional significance of altered Foxa2 binding on 
human G6PC2 promoter activity. A block mutation in the G6PC2 Foxa binding site that 
abolishes Foxa2 binding (Fig. 3.8) also markedly reduces fusion gene expression (Fig. 
3.9) indicating that Foxa2 is an activator in the context of the human G6PC2 promoter, as 
it is in the mouse G6pc2 promoter [79]. Fusion genes containing each rs573225 variant, 
generated in the context of the -324 to +3 (Fig. 3.10) and -8563 to +11 (Fig. 3.11) G6PC2 
promoter regions, were analyzed by transient transfections of βTC-3 cells. Since the loss 
of Foxa2 binding reduces G6PC2 promoter activity (Fig. 3.9) and the rs573225-G allele  
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Figure 3.8. Comparison of Foxa2 binding to the labeled human G6PC2 -265/-246 
and mouse G6pc2 -247/-228 promoter regions in vitro 
Labeled oligonucleotides representing the wild-type (WT) human G6PC2 -265/-246 or 
mouse G6pc2 -247/-228 promoter regions were incubated in the absence or presence of a 
100-fold molar excess of the indicated unlabeled WT or mutant (MUT) competitors. 
βTC-3 nuclear extract was then added and protein binding was analyzed using the gel 
retardation assay as described in Chapter II. In the representative autoradiograph shown, 
only the retarded complexes are visible and not the free probe, which was present in 
excess. The two major complexes detected represent Foxa2 (A2) and non-specific (NS) 
binding. 
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Supplementary Figure 2. The human G6PC2 rs13431652-G allele is associated with 
decreased G6PC2 promoter activity relative to the rs13431652-A allele in the context of the 
pGL4 but not the pGL3 vector. 
 βTC-3 cells were transiently co-transfected, as described in Research Design and 
Methods, using a lipofectamine solution containing human G6PC2-luciferase fusion genes in the 
pGL3 MOD (Panel A) or pGL4 MOD (Panel B) vectors (2 µg) and an expression vector 
encoding Renilla luciferase (0.5 µg). The G6PC2-luciferase fusion genes represented the 
rs13431652-A or -G alleles present in the context of the human G6PC2 promoter sequence 
located between -8563 and +11. Following transfection, cells were incubated for 18-20 hr in 
serum-containing medium. The cells were then harvested and firefly and Renilla luciferase 
activity was assayed as described in Research Design and Methods. Results are presented as the 
ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the value obtained 
with the rs13431652-A allele, and represent the mean of 9-12 experiments ± S.E.M., each using 
an independent preparation of each fusion gene plasmid, assayed in triplicate. *, p < 0.05 versus 
rs13431652-A allele. 
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Supplementary Figure 3. Comparison of Foxa2 binding to the labeled human G6PC2 -265/-
246 and mouse G6pc2 -247/-228 promoter regions in vitro. 
 Labeled oligonucleotides representing the wild-type (WT) human G6PC2 -265/-246 or 
mouse G6pc2 -247/-228 promoter regions were incubated in the absence or presence of a 100-
fold molar excess of the indicated unlabeled WT or mutant (MUT) competitors (Suppl. Table 6). 
βTC-3 nuclear extract was then added and protein binding was analyzed using the gel retardation 
assay as described in Research Design and Methods. In the representative audioradiograph 
shown, only the retarded complexes are visible and not the free probe, which was present in 
excess. The two major complexes detected represent Foxa2 (A2) and non-specific (NS) binding 
(4). 
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Figure 3.9.  Reduction of human G6PC2 and mouse G6pc2 promoter activity by 
marked disruption of Foxa2 binding 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL3 
MOD vector (2 μg) and an expression vector encoding Renilla luciferase (0.5 μg). The 
G6PC2-luciferase fusion genes represented either the wild-type (WT) mouse promoter 
sequence, located between -306 and +3 (Panel A), the WT human promoter sequence 
(rs573225-A allele), located between -324 and +3 (Panel B), or the same sequences with 
a site-directed mutation (SDM) in the Foxa2 binding site. After transfection, cells were 
incubated for 18-20 h in serum-containing medium. The cells were then harvested, and 
firefly and Renilla luciferase activity were assayed as described in Chapter II. Results are 
presented as the ratio of firefly:Renilla luciferase activity, expressed as a percentage 
relative to the value obtained with the WT fusion genes, and represent the mean of three 
experiments ± S.E.M., each using an independent preparation of each fusion gene 
plasmid, assayed in triplicate. *P < 0.05 vs. WT.  
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Supplementary Figure 4. Marked disruption of Foxa2 binding reduces human G6PC2 and 
mouse G6pc2 promoter activity. 
 βTC-3 cells were transiently co-transfected, as described in Research Design and 
Methods, using a lipofectamine solution containing various G6PC2-luciferase fusion genes in the 
pGL3 MOD vector (2 µg) and an expression vector encoding Renilla luciferase (0.5 µg). The 
G6PC2-luciferase fusion genes represented either the wild-type (WT) mouse promoter sequence, 
located between -306 and +3 (Panel A), the WT human promoter sequence (rs573225-A allele), 
located between -324 and +3 (Panel B), or the same sequences with a site-directed mutations 
(SDMs) in the Foxa2 binding sites. The mutations were identical to those used in the gel 
retardation analysis (Suppl. Fig. 3). Following transfection, cells were incubated for 18-20 hr in 
serum-containing medium. The cells were then harvested and firefly and Renilla luciferase 
activity was assayed as described in Research Design and Methods. Results are presented as the 
ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the value obtained 
with the WT fusion genes, and represent the mean of 3 experiments ± S.E.M., each using an 
independent preparation of each fusion gene plasmid, assayed in triplicate. *, p < 0.05 versus 
WT. 
0
25
50
75
100
125
0
25
50
75
100
125
WT Foxa
SDM
Basal
 Expression
Firefly/Renilla
Luciferase
(% Relative
to WT)
A) B)Mouse Human
WT Foxa
SDM
*
*
 
 
	   55 
 
 
 
 
 
 
 
Figure 3.10.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs573225-G allele relative to the rs573225-A allele 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL3 
MOD vector (2 μg) and an expression vector encoding Renilla luciferase (0.5 μg). The 
G6PC2-luciferase fusion genes represented the rs573225-A or rs573225-G alleles present 
in the context of the human G6PC2 promoter sequence located between -324 and +3. 
After transfection, cells were incubated for 18-20 h in serum-containing medium. The 
cells were then harvested, and firefly and Renilla luciferase activity were assayed as 
described in Chapter II. Results are presented as the ratio of firefly:Renilla luciferase 
activity, expressed as a percentage relative to the value obtained with the rs573225-A 
allele, and represent the mean of three experiments ± S.E.M., each using an independent 
preparation of each fusion gene plasmid, assayed in triplicate. *P < 0.05 vs. rs573225-A 
allele. 
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Figure 3.11.  Interaction between the G6PC2 rs13431652-G and rs573225-G alleles 
on G6PC2 promoter activity 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL4 
MOD vector (2 μg) and an expression vector encoding Renilla luciferase (0.5 μg). The 
G6PC2-luciferase fusion genes represented the rs573225-A or rs573225-G alleles and 
rs13431652-A or rs13431652-G alleles present in the context of the human G6PC2 
promoter sequence located between -8563 and +11. After transfection, cells were 
incubated for 18-20 h in serum-containing medium. The cells were then harvested, and 
firefly and Renilla luciferase activity were assayed as described in Chapter II. Results are 
presented as the ratio of firefly:Renilla luciferase activity, expressed as a percentage 
relative to the value obtained with the rs573225-A and rs13431652-A alleles, and 
represent the mean of eight experiments ± S.E.M., each using an independent preparation 
of each fusion gene plasmid, assayed in triplicate. *P < 0.05 vs. rs573225-A and 
rs13431652-A alleles. 
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decreases Foxa2 binding (Fig. 3.7C), we anticipated that the rs573225-G allele would 
also be associated with reduced G6PC2 promoter activity. Surprisingly, Figures 3.10 and 
3.11 show that the rs573225-G allele was actually associated with an increase in 
promoter activity in comparison to that observed with the rs573225-A allele. This result 
is not explained by the de novo creation of an activator binding site by the rs573225-G 
allele (Fig. 3.6B). Figures 3.12 and 3.13 show that a similar effect of the rs573225-G 
allele was also seen in the HIT and Min6 cell lines and when the G6PC2 promoter was 
analyzed in the context of both the pGL4 and pGL3 vectors, respectively. Since the 
Foxa2 binding site incorporates the target sequence for the bacterial Dam methylase 
(GATC), we repeated this analysis using plasmids grown in SCS110 Dam and Dcm 
methylase deficient bacteria. Figure 3.14 shows that Dam methylation of the Foxa2 
binding site did not alter the stimulatory effect of rs573225 on fusion gene expression. 
While the increased promoter activity observed with the rs573225-G allele was 
unexpected, given the reduction in Foxa2 binding, the key observation here is that the 
functional data obtained with rs573225 are not consistent with the reduced FPG observed 
in G6pc2 knockout mice [55] in that the rs573225-A allele is associated with elevated 
FPG (Table 3.1) but reduced G6PC2 promoter activity. As such, in contrast to the 
functional data obtained with rs13431652, these functional data do not support a potential 
role for rs573225 as a causative SNP linking G6PC2 to variations in FPG. 
 Because endogenous G6PC2 gene expression will reflect the combined effects of 
multiple SNPs we investigated the interaction between rs573225 and rs13431652 on 
G6PC2 fusion gene expression (Fig. 3.11). The results show a trend toward the 
rs13431652-G allele blunting the elevated expression conferred by the rs573225-G allele,  
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Figure 3.12.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs573225-G allele relative to the rs573225-A allele in multiple cell lines 
βTC-3 (Panel A), HIT (Panel B), and Min6 (Panel C) cells were transiently cotransfected, 
as described in Chapter II, using a lipofectamine solution containing various G6PC2-
luciferase fusion genes in the pGL3 MOD vector (2 μg) and an expression vector 
encoding Renilla luciferase (0.5 μg). The G6PC2-luciferase fusion genes represented the 
rs573225-A or rs573225-G alleles alleles present in the context of the human G6PC2 
promoter sequence located between -324 and +3. After transfection, cells were incubated 
for 18-20 h in serum-containing medium. The cells were then harvested, and firefly and 
Renilla luciferase activity were assayed as described in Chapter II. Results are presented 
as the ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the 
value obtained with the rs573225-A allele, and represent the mean of three experiments ± 
S.E.M., each using an independent preparation of each fusion gene plasmid, assayed in 
triplicate. *P < 0.05 vs. rs573225-A allele. 
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Supplementary Figure 5. The human G6PC2 rs573225-G allele is associated with increased 
G6PC2 promoter activity relative to the rs573225-A allele. 
 βTC-3 (Panel A), HIT (Panel B) and Min6 (Panel C) cells were transiently co-
transfected, as described in Research Design and Methods, using a lipofectamine solution 
containing various G6PC2-luciferase fusion genes in the pGL3 MOD vector (2 µg) and an 
expression vector encoding Renilla luciferase (0.5 µg). The G6PC2-luciferase fusion genes 
represented the rs573225-A or G alleles present in the context of the human G6PC2 promoter 
sequence located between -324 and +3. Following transfection, cells were incubated for 18-20 hr 
in serum-containing medium. The cells were then harvested and firefly and Renilla luciferase 
activity was assayed as described in Research Design and Methods. Results are presented as the 
ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the value obtained 
with the rs573225-A allele, and represent the mean of 3 experiments ± S.E.M., each using an 
independent preparation of each fusion gene plasmid, assayed in triplicate. *, p < 0.05 versus 
rs573225-A allele. 
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Figure 3.13.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs573225-G allele relative to the rs573225-A allele in pGL3 and pGL4 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL3 
MOD (Panel A) or pGL4 MOD (Panel B) vectors (2 μg) and an expression vector 
encoding Renilla luciferase (0.5 μg). The G6PC2-luciferase fusion genes represented the 
rs573225-A or rs573225-G alleles present in the context of the human G6PC2 promoter 
sequence located between -324 and +3. After transfection, cells were incubated for 18-20 
h in serum-containing medium. The cells were then harvested, and firefly and Renilla 
luciferase activity were assayed as described in Chapter II. Results are presented as the 
ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the value 
obtained with the rs573225-A allele, and represent the mean of three experiments ± 
S.E.M., each using an independent preparation of each fusion gene plasmid, assayed in 
triplicate. *P < 0.05 vs. rs573225-A allele. 
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Supplementary Figure 6. The human G6PC2 rs573225-G allele is associated with increased 
G6PC2 promoter activity relative to the rs573225-A allele in the context of the pGL3 and 
pGL4 vectors. 
 βTC-3 cells were transiently co-transfected, as described in Research Design and 
Methods, using a lipofectamine solution containing human G6PC2-luciferase fusion genes in the 
pGL3 MOD (Panel A) or pGL4 MOD (Panel B) vectors (2 µg) and an expression vector 
encoding Renilla luciferase (0.5 µg). The G6PC2-luciferase fusion genes represented the 
rs573225-A or -G alleles present in the context of the human G6PC2 promoter sequence located 
between -324 and +3. Following transfection, cells were incubated for 18-20 hr in serum-
containing medium. The cells were then harvested and firefly and Renilla luciferase activity was 
assayed as described in Research Design and Methods. Results are presented as the ratio of 
firefly:Renilla luciferase activity, expressed as a percentage relative to the value obtained with 
the rs573225-A allele, and represent the mean of 3 experiments ± S.E.M., each using an 
independent preparation of each fusion gene plasmid, assayed in triplicate. *, p < 0.05 versus 
rs573225-A allele. 
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Figure 3.14.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs573225-G allele relative to the rs573225-A allele independent of DNA methylation 
status 
βTC-3 cells were transiently cotransfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL3 
MOD vectors (2 μg) and an expression vector encoding Renilla luciferase (0.5 μg). The 
G6PC2-luciferase fusion genes represented the rs573225-A or rs573225-G alleles present 
in the context of the human G6PC2 promoter sequence located between -324 and +3. The 
fusion gene plasmids were grown in methylase containing DH5α (Panel A) or methylase 
deficient SCS110 (Panel B) bacterial cells. After transfection, cells were incubated for 
18-20 h in serum-containing medium. The cells were then harvested, and firefly and 
Renilla luciferase activity were assayed as described in Chapter II. Results are presented 
as the ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the 
value obtained with the rs573225-A allele, and represent the mean of three experiments ± 
S.E.M., each using an independent preparation of each fusion gene plasmid, assayed in 
triplicate. *P < 0.05 vs. rs573225-A allele.  
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Supplementary Figure 7. The human G6PC2 rs573225-G allele is associated with increased 
G6PC2 promoter activity relative to the rs573225-A allele independent of DNA methylation 
status. 
 βTC-3 cells were transiently co-transfected, as described in Research Design and 
Methods, using a lipofectamine solution containing various G6PC2-luciferase fusion genes in the 
pGL3 MOD vector (2 µg) and an expression vector encoding Renilla luciferase (0.5 µg). The 
G6PC2-luciferase fusion genes represented the rs573225-A or -G alleles present in the context of 
the human G6PC2 promoter sequence located between -324 and +3. The fusion gene plasmids 
were grown in methylase containing DH5α (Panel A) or methylase deficient SCS110 (Panel B) 
bacterial cells. Following transfection, cells were incubated for 18-20 hr in serum-containing 
medium. The cells were then harvested and firefly and Renilla luciferase activity was assayed as 
described in Research Design and Methods. Results are presented as the ratio of firefly:Renilla 
luciferase activity, expressed as a percentage relative to the value obtained with the WT fusion 
genes, and represent the mean of 3 experiments ± S.E.M., each using an independent preparation 
of each fusion gene plasmid, assayed in triplicate. *, p < 0.05 versus rs573225-A allele. 
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though, because of the relatively small effects involved and the inherent variability in 
transient transfections, the decrease did not reach statistical significance. 
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Discussion 
Genome-wide association studies have recently provided important new insights 
about the genetics of common forms of type 2 diabetes and its related quantitative traits, 
especially for FPG [43, 91, 107]. After this first discovery phase, attention is now 
beginning to focus on the study of the functional properties of the variants at the 
confirmed loci. In this study, using a combination of genetic and functional data we 
provide further genetic support for the primary contribution of G6PC2 to variations in 
FPG, a conclusion supported by other genetic studies [90, 108-110]. Furthermore, it is 
specifically demonstrated that 1) the 'A' allele of the common variant rs13431652 is 
strongly associated with elevated FPG, 2) the rs13431652-A allele enhances NF-Y 
binding to the G6PC2 promoter (Figs. 3.2 & 3.3) and 3) increases fusion gene expression 
(Fig. 3.4). Although no significant correlation between endogenous G6PC2 gene 
expression and rs13431652 genotypes was observed, probably due to the limited sample 
analyzed (N = 24), the in vitro data are consistent with the reduced FPG observed in 
G6pc2 knockout mice [55] and the hypothesis that G6PC2 expression would oppose the 
action of glucokinase leading to elevated FPG. These data suggest that rs13431652 is a 
strong candidate to be a causative SNP that contributes to the association signal between 
G6PC2 and FPG, though it is important to note that our genetic data do not rule out a 
significant contribution of the intronic variant rs560887. Future studies will be designed 
to address our hypothesis that this SNP affects G6PC2 mRNA splicing [43]. 
Our study does not give support to the contribution of intronic variant rs853789 
located in the 19th intron of ABCB11 to the association signal with FPG in our European 
cohorts. In a recent study conducted in Asian populations, a haplotype tagging variant 
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rs3755157 located in the 21st intron of ABCB11 was identified as associated with FPG 
independently from rs560887, which may support the existence of two independent 
signals at this locus [111]. In this paper, limited attention was given to the striking 
differences in alleles frequencies between Asians and Europeans both at rs560887 
(MAFEU = 0.30 vs. MAFAs = 0.03) and rs3755157 (0.12 calculated in our French 
population and 0.09 in HapMap CEU population vs. MAFAs = 0.38). We believe that 
these differences may alter the efficiency of these two SNPs to tag putative causal 
variant(s), as reflected by the difference in the strength of the associations of these SNPs 
observed in Europeans vs. Asians. Nonetheless, we acknowledge that a more extensive 
fine mapping analysis, involving a larger number of variants in this locus, will be 
required to elucidate the contribution of G6PC2 and ABCB11 variants to the association 
signal and provide a more comprehensive genetic assessment of this important locus in 
the genetic determination of FPG. 
Using a combination of genetic and functional data we show that rs573225-A 
allele is highly associated with elevated FPG (Table 3.1), enhanced Foxa2 binding (Figs. 
3.6 & 3.7) but lower fusion gene expression (Fig. 3.10), a correlation that is inconsistent 
with the reduced FPG observed in G6pc2 knockout mice [55]. As such, unlike the 
functional data obtained with rs13431652, these functional data do not support a potential 
role for rs573225 as a causative SNP linking G6PC2 to variations in FPG. In contrast, 
Dos Santos et al. recently concluded that rs573225 was the causative SNP that explained 
the association signal between FPG and G6PC2 [92]. As in our study they observed that 
the rs573225-A allele is associated with elevated FPG but lower fusion gene expression 
but they did not comment on the fact that these data are inconsistent with the function of 
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G6PC2. Dos Santos et al. also suggested that rs573225 is an epiSNP because the 
rs573225-G allele is located at a GpC dinucleotide within the Foxa2 binding site and 
methylation of the 'C' nucleotide affected Foxa2 binding [92]. However, in contrast to the 
well-studied methylation of CpG dinucleotides [112], we can find no reports of the 
existence of methylated GpC dinucleotides in mammals, though such a modification does 
exist in fish [113]. Finally, while our fusion gene data match that of Dos Santos et al. [92] 
our gel retardation results are the complete opposite. Dos Santos et al. report that the 
rs573225-G allele binds Foxa2 whereas the rs573225-A allele completely abolishes 
Foxa2 binding [92]. Their binding data therefore appear to correlate with their fusion 
gene data since the rs573225-G allele confers higher promoter activity. However, a 
detailed previous study by Overdier et al. showed that both 'G' and 'A' nucleotides at this 
location within the Foxa2 binding site support Foxa2 binding [114]. Our demonstration 
that Foxa2 binds with the same affinity to both alleles (Fig. 3.7A & B), though with 
different kinetics (Fig. 3.7C), is therefore consistent with the observations of Overdier et 
al. [114], but not those of Dos Santos et al. [92]. Moreover, given the importance of 
Foxa2 for G6PC2 fusion gene expression (Fig. 3.9), if the rs573225-A allele were to 
abolish Foxa2 binding Dos Santos et al. should have detected a major difference in the 
level of reporter gene expression conferred by the promoters containing the rs573225-A 
and -G alleles instead of the ~15% difference reported [92]. 
Although the available data does not support a role for rs573225 as a causative 
SNP, a caveat with the experiments reported here is that the functional effect of rs573225 
on endogenous G6PC2 gene transcription in vivo may not be replicated by analyses 
involving the transient transfection of fusion genes in islet-derived cell lines. Thus, fusion 
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gene experiments have several limitations including 1) the absence of chromatin structure 
in transient transfection assays [115], 2) the use of a truncated fusion gene that lacks the 
five known G6PC2 transcriptional enhancers [75], and 3) the use of tissue culture cell 
lines whose gene expression profiles do not match that of islets in vivo. All of these 
factors have the potential to alter the affect of rs573225 on G6PC2 gene transcription. 
Finally, Foxa2 is known to act as a pioneer factor opening chromatin to allow access of 
other transcription factors [116]. As such, rs573225 may have different effects on G6PC2 
gene expression early in development than in adults. 
In summary, our study provides genetic and functional evidence supporting an 
important role for the promoter variant rs13431652 as a potentially causative SNP that 
contributes to the association signal between G6PC2 and FPG but the data do not 
preclude a significant contribution of the intronic variant rs560887, or other additional 
unidentified variants. 
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CHAPTER IV 
 
FUNCTIONAL DATA SUPPORT A POTENTIAL ROLE FOR rs2232316 AS A 
CAUSATIVE G6PC2 SNP CONTRIBUTING TO VARIATION IN FPG 
 
 
Introduction 
 The conflicting results regarding the rs573225 SNP in the previous set of 
experiments necessitated further exploration of this SNP, as well as another, rs2232316, 
located in its vicinity. Because the rs573225-A allele was associated with increased FPG 
but reduced promoter activity in fusion gene analyses [96], at odds with the putative 
function of G6PC2 in pancreatic islets, it is possible that the behavior of this SNP in 
tissue culture cells does not accurately reflect its effect on G6PC2 gene transcription in 
vivo. Conversely, the consistencies seen between the genetic and promoter activity data 
for rs13431652 and the conclusions drawn from them in previous studies [96] may be 
incorrect in the unlikely event that human G6PC2 and mouse G6pc2 have opposite 
effects on FPG, in which case, the behavior of rs13431652 in tissue culture cells may not 
accurately portray the effect of this SNP on G6PC2 gene transcription in vivo. To lend 
credence to one of these two possibilities, additional functional studies were performed 
on the role of rs573225. Furthermore, new studies were carried out to examine the effect 
of rs2232316 on transcription factor binding, G6PC2 fusion gene expression, and its 
genetic association with FPG in humans. 
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Results 
 
rs2232316 alters Foxa2 binding to the G6PC2 promoter in vitro 
 The G6PC2 promoter region that encompasses rs2232316, located at -238 relative 
to the transcription start site, was analyzed using MatInspector sequence analysis 
software [99] with the goal of identifying a cis-acting element whose binding of its 
cognate trans-acting factor was likely to be affected by the alternate rs2232316 alleles. 
This analysis identified a forkhead transcription factor binding motif [117].  
 While several members of the Fox family are expressed in the pancreas [117], 
members of the Foxa sub-group have been shown to play important roles in islet 
development and function [105]. Gel retardation assays were used to investigate whether 
any of the three Foxa isoforms [105] can bind to this G6PC2 promoter region in vitro. 
When a labeled double-stranded oligonucleotide, designated rs2232316-A, representing 
the G6PC2 promoter sequence from -250 to -226 and the rs2232316-A allele (Fig. 4.1A), 
was incubated with nuclear extract prepared from βTC-3 cells a single protein-DNA 
complex was detected (Fig. 4.1B). To identify the factor present in this complex a gel 
retardation assay was performed in which βTC-3 cell nuclear extract was pre-incubated 
with antisera specific for Foxa2 or, as a control, USF-2. Previous studies have shown that 
Foxa2 is the predominant Foxa isoform in βTC-3 cells [79]. As can be seen in Figure 
4.1B, addition of antibodies recognizing Foxa2 resulted in a clear supershift in the 
migration of the complex whereas addition of antibodies recognizing USF-2 had no 
effect. This result strongly suggests that the complex represents Foxa2 binding. 
 Gel retardation competition experiments, in which a varying molar excess of  
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Figure 4.1.  Binding of the -250/226 promoter region of G6PC2 by Foxa2 in vitro 
(A) The sense strand sequences of the oligonucleotides used in gel retardation assays are 
shown. SNP base pairs are shown in bold lower case letters. The consensus Foxa binding 
motif, (A/G)A(G/A)(C/T)(C/A)AA(C/T)A(T/A)T(T/G/C), is taken from Overdier et al. 
(B) βTC-3 nuclear extract was incubated in the absence (None) or presence of the 
indicated anti-serum for 10 minutes on ice. A labeled oligonucleotides representing the -
250/-226 G6PC2 promoter region and containing the rs2232316-A allele (rs2232316-A; 
Panel A) was then added and incubation continued for 20 min at room temperature. 
Protein binding was then analyzed using the gel retardation assay as described in Chapter 
II. In the representative autoradiograph shown, only the retarded complexes are visible 
and not the free probe, which was present in excess. A single major complex was 
detected that represents Foxa2 binding. The arrow indicates a supershifted complex. 
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unlabeled DNA was included with the labeled rs2232316-A oligonucleotide, were used to 
compare the affinity of Foxa2 binding to the rs2232316 variants of this G6PC2 Foxa2 
binding site. Figure 4.2 (Panels A and B) shows that the rs2232316-A oligonucleotide 
competed effectively for the formation of the Foxa2-DNA complex whereas the 
rs2232316-G oligonucleotide did not. Consistent with the competition experiment data 
(Fig. 4.2A and B), the direct analysis of Foxa2 binding to the rs2232316-A and -G 
oligonucleotide probes, labeled with the identical specific activity, showed a dramatic 
difference in Foxa2 binding affinity (Fig. 4.2C). Interestingly, the original consensus 
sequence for Foxa2 binding (Fig. 4.1A; Ref. [114]) indicates that either an 'A' or a 'G' 
nucleotide at the location of the rs2232316 SNP will support Foxa2 binding, but clearly 
this is not the case (Fig. 4.2C). However, this consensus was established using a 
sequential selection and amplification of binding sites protocol [114]. In contrast, an 
analysis of endogenous Foxa2 binding sites based on ChIP-Seq data [118] indicates that 
an 'A' nucleotide is preferred at the location of the rs2232316 SNP in vivo, consistent 
with the binding data (Fig. 4.2C). Both methods indicate that a 'G' or a 'T' nucleotide is 
preferred at the location immediately 5' of the rs2232316 SNP [114, 118], whereas in the 
G6PC2 promoter a 'C' nucleotide is present at this location (Fig. 4.1A). We speculate that 
the presence of this 'C' nucleotide may have accentuated the preference for an 'A' 
nucleotide at the location of the adjacent rs2232316 SNP. 
 
rs2232316 alters G6PC2 fusion gene expression in βTC-3 cells 
 We next investigated the functional significance of altered Foxa2 binding on 
human G6PC2 promoter activity. Fusion genes containing each of the rs2232316 alleles,  
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Figure 4.2.  Comparison of the effect of the rs2232316-A and -G alleles on Foxa2 
binding affinity in vitro 
(A) The labeled rs2232316-A oligonucleotide (Fig. 4.1A) was incubated in the absence or 
presence of the indicated molar excess of the unlabeled human rs2232316-A or –G 
oligonucleotide competitors (Fig. 4.1A) prior to the addition of βTC-3 cell nuclear 
extract. Protein binding was then analyzed using the gel retardation assay as described in 
Chapter II. In the representative autoradiograph shown only the retarded complex is 
visible and not the free probe, which was present in excess. (B) Protein binding, 
specifically 32P associated with the retarded complex, was quantified as described in 
Chapter II. The data represents the mean ± S.E.M. of three experiments. (C) The labeled 
rs2232316-A and –G oligonucleotides (Fig. 4.1A) were incubated with βTC-3 cell 
nuclear extract and protein binding was analyzed using the gel retardation assay as 
described in Chapter II. In the representative autoradiograph shown, only the retarded 
complexes are visible and not the free probe, which was present in excess. NS, non-
specific. 
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generated in the context of the -324 to +3 G6PC2 promoter region, were analyzed by 
transient transfection of βTC-3 cells. Figure 4.3 shows that the rs2232316-A allele was 
associated with an approximately 50% increase in promoter activity in comparison to that 
observed with the rs2232316-G allele. Figure 4.4 shows that a similar effect of the 
rs2232316-A allele was also seen in the HIT and Min6 islet-derived cell lines. In 
summary, the functional and genetic data for rs2232316 correlate, with the rs2232316-A 
allele being associated with both elevated G6PC2 promoter activity (Fig. 4.3) and FPG 
(Table 4.1), thereby supporting a potential role for rs2232316 as a causative SNP linking 
G6PC2 to variations in FPG. 
 
rs2232316 does not influence the effect of rs573225 on G6PC2 fusion gene expression 
in βTC-3 cells 
 
 We recently showed that the alternate alleles of rs573225 also alter Foxa2 binding 
to the G6PC2 promoter in vitro [96]. The Foxa2 binding sites that encompass rs573225 (-
261/-250) and rs2232316 (-246/-235) are located 3 bp apart in the G6PC2 promoter and 
this region is highly conserved in the mouse G6pc2 promoter [36]. Furthermore, 
chromatin immunoprecipitation (ChIP) assays show that Foxa2 binds this region of the 
endogenous G6pc2 promoter in mouse βTC-3 cells in situ [79].  
 rs573225 has a paradoxical effect on G6PC2 fusion gene expression. A block 
mutation in the G6PC2 Foxa2 binding site that encompasses rs573225 abolishes Foxa2 
binding and also markedly reduces fusion gene expression indicating that Foxa2 acts as 
an activator when bound to this site in the human G6PC2 promoter [96], as it does when 
bound to the equivalent site in the mouse G6pc2 promoter [79]. Since the loss of Foxa2 
binding to this site reduces G6PC2 promoter activity and because the rs573225-G allele  
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Figure 4.3.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs2232316-A allele relative to the rs2232316-G allele in βTC-3 cells 
βTC-3 cells were transiently co-transfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-luciferase fusion genes in the pGL3 
MOD vector (2 μg) and an expression vector encoding Renilla luciferase (0.5 μg). The 
G6PC2-luciferase fusion genes represented the rs2232316-A or rs2232316-G alleles and 
rs573225-A or rs573225-G alleles present in the context of the human G6PC2 promoter 
sequence located between -324 and +3. After transfection, cells were incubated for 18-20 
h in serum-containing medium. The cells were then harvested, and firefly and Renilla 
luciferase activity were assayed as described in Chapter II. Results are presented as the 
ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the value 
obtained with the rs2232316-G and rs573225-A alleles, and represent the mean of three 
experiments ± S.E.M., each using an independent preparation of each fusion gene 
plasmid, assayed in triplicate. *P < 0.05 vs. rs2232316-G and rs573225-A allele. **P < 
0.05 vs. (rs2232316-G and rs573225-G) and (rs2232316-A and rs573225-A) alleles. 
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Figure 4.4.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs2232316-A allele relative to the rs2232316-G allele in multiple cell lines 
βTC-3 (Panel A), HIT (Panel B), and Min6 (Panel C) cells were transiently cotransfected, 
as described in Chapter II, using a lipofectamine solution containing various G6PC2-
luciferase fusion genes in the pGL3 MOD vector (2 μg) and an expression vector 
encoding Renilla luciferase (0.5 μg). The G6PC2-luciferase fusion genes represented the 
rs2232316-A or rs2232316-G alleles alleles present in the context of the human G6PC2 
promoter sequence located between -324 and +3. After transfection, cells were incubated 
for 18-20 h in serum-containing medium. The cells were then harvested, and firefly and 
Renilla luciferase activity were assayed as described in Chapter II. Results are presented 
as the ratio of firefly:Renilla luciferase activity, expressed as a percentage relative to the 
value obtained with the rs573225-A allele, and represent the mean of three experiments ± 
S.E.M., each using an independent preparation of each fusion gene plasmid, assayed in 
triplicate. *P < 0.05 vs. rs2232316-G allele. 
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Table 4.1.  Association with fasting plasma glucose in D.E.S.I.R. participants 
The table shows the effect allele frequencies, genotype groups and numbers, mean fasting 
plasma glucose (with standard deviation per genotype group), regression coefficient β 
(with standard error) and associated p-value (P). 
 
SNP Effect allele (Freq.) 
Genotype 
(N) 
Mean FG 
(SD) β (SE) P 
rs573225 A (0.66) GG (471) 5.11 (0.02)    
 
  GA (1847) 5.16 (0.01)   
 
  AA (1865) 5.25 (0.01) 0.08 (0.01) 3.7x10
-17 
rs2232316 A (0.11) GG (3320) 5.18 (0.01)    
 
  GA (850) 5.24 (0.01)   
 
  AA (49) 5.21 (0.07) 0.05 (0.01) 7.2x10
-4 
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decreases Foxa2 binding [96] we anticipated that the rs573225-G allele would also be 
associated with reduced G6PC2 promoter activity. Surprisingly, the rs573225-G allele is 
associated with an increase in promoter activity in comparison to that observed with the 
rs573225-A allele (Fig. 4.3) [96]. Because the Foxa2 binding sites that encompass 
rs573225 and rs2232316 are so close we hypothesized that Foxa2 binding at one element 
may modulate the action of Foxa2 at the other. The interaction between these SNPs on 
G6PC2 fusion gene expression was therefore investigated (Fig. 4.3). The results show 
that the rs573225-G allele and the rs2232316-A allele have an additive and, therefore, 
apparently independent effect on reporter gene expression (Fig. 4.3). 
 
The rs2232316 G6PC2 promoter variant is associated with FPG but not 
independently from rs573225 
 
 We assessed the association of the promoter variant rs2232316 with FPG levels in 
4,364 normal fasting glucose participants (FPG < 6.1 mmol/L) from the D.E.S.I.R cohort. 
In accord with the fusion gene data, we found that the rs2232316-A allele associates with 
increased FPG (β = 0.05, P = 7.2×10-4) (Table 4.1). This association was replicated (β = 
0.04, P = 7.3×10-10) using in silico analysis computed in 45,688 non-diabetic participants 
of European descent in MAGIC (Meta-Analysis of Glucose and Insulin Consortium) 
[119].  Conditioned regression model analyses in D.E.S.I.R to assess the independency 
from rs573225 showed a lack of significance of rs2232316 (P = 0.26) when we took into 
account the effect of rs573225.  Specifically no significant effect of rs2232316 was found 
in individuals where we fixed rs573225 (association of rs2232316 with FPG in rs573225-
AA carriers: β = 0.02, P = 0.17; rs573225-AG carriers: β = 0.01, P = 0.77; and rs573225-
GG carriers: β = -0.39, P = 0.17). However, despite a low correlation between the two 
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variants (r² = 0.04, HapMap III data, r2 = 0.06 in D.E.S.I.R.) due to important differences 
in frequency of the effect alleles (Freqrs573225-A = 0.67 vs. Freqrs2232316-A = 0.11), we 
observed high linkage disequilibrium between the two variants (D’ = 0.98) indicating that 
both associations represent a single signal. As such, this implies that both rs573225 and 
rs2232316 have the potential to be causative variants. 
 In summary the genetic data support a potential role for rs2232316 as a causative 
SNP linking G6PC2 to variations in FPG. In the case of rs2232316, the functional and 
genetic data correlate with the association between the rs2232316-A allele with elevated 
G6PC2 promoter activity (Fig. 4.3) and FPG (Table 4.1). 
 
rs573225 and rs2232316 influence G6PC2 fusion gene expression in an artificial cell 
system 
 
 Of the SNPs we have analyzed to date, the three that affected G6PC2 promoter 
activity (rs13431652, rs573225 and rs2232316) all affected FPG (Table 4.2). Since it 
seems highly unlikely that mouse G6pc2 and human G6PC2 have opposite functions 
given the high level of sequence conservation [36], the data for rs13431652 and 
rs2232316 are consistent with the reduced FPG observed in G6pc2 knockout mice [55] 
and therefore a role for these variants as potentially causative SNPs (Table 4.1). These 
data also imply that the behavior of rs573225 in several islet-derived cell lines (Fig. 3.12; 
Ref. [96]) does not accurately reflect its effect on G6PC2 gene transcription in vivo. 
 Given this apparent limitation of islet-derived cell lines with respect to rs573225 
we decided to examine the action of rs573225 and rs2232316 on G6PC2 fusion gene 
expression in a previously described reconstituted cell system in which HeLa cells, a 
cervix-derived cell line [120], are co-transfected with G6PC2 fusion genes and  
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Table 4.2.  Summary of the functional and genetic properties of G6PC2 promoter 
SNPs 
 
SNP Promoter Location 
Effect on 
Binding 
Effect on 
Transcription 
in βTC-3 
Cells 
Effect on 
Transcription 
in HeLa 
Cells 
Effect on 
FPG 
rs13431652-
A -4385 
NF-Y 
Binding Up Up N.D. Up 
rs573225-A -259 Foxa2 Binding Up Down Up Up 
rs2232316-
A -238 
Foxa2 
Binding Up Up Down Up 
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expression vectors encoding the islet-enriched transcription factors Pdx-1, Pax-6, MafA, 
and NeuroD, with its heterodimerization partner E47 [79]. Individually, with the 
exception of NeuroD, none of these transcription factors markedly induce G6PC2 fusion 
gene expression in HeLa cells whereas together they act synergistically to strongly induce 
expression [79]. The results show that in HeLa cells, in contrast to βTC-3 cells (Fig. 4.3), 
the rs573225-G allele is now associated with reduced G6PC2 fusion gene expression 
(Fig. 4.5), consistent with the genetic data (Table 4.1). This effect was blunted when 
Foxa2 was also overexpressed (Fig. 4.6). Similarly in HeLa cells, in contrast to βTC-3 
cells (Fig. 4.3), the rs2232316-A allele is now associated with reduced G6PC2 fusion 
gene expression (Fig. 4.5), an effect that was reversed when Foxa2 was also 
overexpressed (Fig. 4.6). While these latter functional data with rs2232316 remain 
consistent with the genetic data, these HeLa cell experiments suggest that, under specific 
conditions, the rs573225-G allele is associated with reduced G6PC2 fusion gene 
expression, consistent with the genetic data. These data also suggest that the action of 
rs573225 and rs2232316 on G6PC2 gene expression in vivo will be critically dependent 
on Foxa2 levels. 
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Figure 4.5.  Increased G6PC2 promoter activity associated with the human G6PC2 
rs573225-A allele relative to the rs573225-G allele in HeLa cells 
HeLa cells were transiently co-transfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-CAT fusion genes (2 μg), a SV40-
firefly luciferase expression vector (0.5 μg), and expression vectors (0.02 μg each) 
encoding Pdx-1, Pax-6, MafA, NeuroD and E47. The G6PC2-CAT fusion genes 
represented the rs2232316-A or –G alleles and rs573225-A or rs573225-G alleles present 
in the context of the human G6PC2 promoter sequence located between -324 and +3. 
After transfection, cells were incubated for 18-20 h in serum-free medium. The cells were 
then harvested, and both CAT and luciferase activities were assayed as described in 
Chapter II. Results were calculated as the ratio of CAT and luciferase activities in the 
same sample and are expressed as a percentage relative to the value obtained in the 
presence of the rs2232316-G and rs573225-A alleles. Results represent the mean of three 
experiments ± S.E.M., each using an independent preparation of each fusion gene 
plasmid with each condition, assayed in triplicate. *P < 0.05 vs. rs2232316-G and 
rs573225-A allele. 
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Figure 4.6.  Abrogation of changes in G6PC2 promoter activity with respect to 
human G6PC2 rs573225 in HeLa cells overexpressing Foxa2 
HeLa cells were transiently co-transfected, as described in Chapter II, using a 
lipofectamine solution containing various G6PC2-CAT fusion genes (2 μg), a SV40-
firefly luciferase expression vector (0.5 μg), and expression vectors (0.02 μg each) 
encoding Pdx-1, Pax-6, MafA, NeuroD, E47, and Foxa2. The G6PC2-CAT fusion genes 
represented the rs2232316-A or –G alleles and rs573225-A or rs573225-G alleles present 
in the context of the human G6PC2 promoter sequence located between -324 and +3. 
After transfection, cells were incubated for 18-20 h in serum-free medium. The cells were 
then harvested, and both CAT and luciferase activities were assayed as described in 
Chapter II. Results were calculated as the ratio of CAT and luciferase activities in the 
same sample and are expressed as a percentage relative to the value obtained in the 
presence of the rs2232316-G and rs573225-A alleles. Results represent the mean of three 
experiments ± S.E.M., each using an independent preparation of each fusion gene 
plasmid with each condition, assayed in triplicate. *P < 0.05 vs. rs2232316-G and 
rs573225-A allele.  
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Discussion 
 Genome-wide association studies have recently provided important new insights 
about the genetics of common forms of type 2 diabetes and some of its related 
quantitative traits such as FPG and HbA1C [43, 90, 91, 107-110, 119, 121-124]. After this 
first discovery phase, attention is now beginning to focus on the analysis of the functional 
properties of the variants at the confirmed loci. Such studies can initially be driven by 
genetic data [96] or, as here, by the identification of a SNP with a marked functional 
effect. In either case, it is the combination of genetic and functional data together that are 
essential for assessing the importance of individual human genetic variants. 
 In a previous study we examined the contribution of two G6PC2 promoter SNPs, 
rs13431652 and rs573225, to the association signal between G6PC2 and FPG. The 
rs13431652-A allele was associated with increased FPG and elevated G6PC2 promoter 
activity, whereas the rs573225-A allele was associated with increased FPG but reduced 
G6PC2 promoter activity [96]. The rs13431652 data are consistent with the function of 
G6PC2 in pancreatic islets based on the analysis of G6pc2 knockout mice [55] and the 
resulting hypothesis that G6PC2 opposes the action of glucokinase, such that elevated 
G6PC2 expression would lead to elevated FPG. Since it is unlikely that human G6PC2 
and mouse G6pc2 have opposite effects on FPG, the most plausible interpretation of 
these data is that the behavior of the rs573225 SNP in islet-derived cell lines does not 
accurately reflect its effect on G6PC2 gene transcription in vivo. This hypothesis is 
consistent with the results of the present study in which, again using a combination of 
genetic and functional data, we show that in islet-derived cell lines the behavior of a 
second promoter SNP accurately reflects its effect on G6PC2 gene transcription in vivo. 
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Thus the rs2232316-A allele is associated with elevated G6PC2 promoter activity (Fig. 
4.3) and FPG (Table 4.1). Furthermore, we show that regardless of the nature of the 
rs2232316 allele, the rs573225-A allele that is associated with increased FPG (Table 4.1) 
is associated with reduced G6PC2 promoter activity (Fig. 4.3). Therefore while the 
genetic data support a potential role for rs13431652, rs2232316, and rs573225 as 
causative SNPs linking G6PC2 to variations in FPG, the functional data suggest that only 
the action of rs13431652 and rs2232316 on G6PC2 fusion gene expression in islet-
derived cell lines mimics its effect on endogenous G6PC2 gene expression in vivo. 
Strikingly, in contrast to the results obtained using islet-derived cell lines, functional data 
from a HeLa cell reconstituted cell system (Fig. 4.5) showed that the rs573225-A allele 
was associated with elevated G6PC2 promoter activity which correlates with the genetic 
data (Table 4.1) and is consistent with the function of G6PC2 in pancreatic islets, thereby 
supporting a role for rs573225 as a causative SNP. Ideally we would like to obtain 
additional support for these conclusions through the analysis of endogenous G6PC2 
expression in pancreatic islets; however, previous experience has shown that the limited 
sample sizes available from human cadavers are insufficient to detect significant 
correlations [96]. 
 Dos Santos et al. [92] recently concluded that rs573225 was an epiSNP and the 
causative variant that explained the association signal between FPG and G6PC2. While 
our genetic data and theirs support a potential role for rs573225 as a causative SNP 
linking G6PC2 to variations in FPG, as previously noted [96] their binding data were at 
odds with previous studies on DNA methylation in mammals [112] and Foxa2 binding 
[114] while their transfection data in an islet-derived cell line, as with ours, was at odds 
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with the role of G6PC2 in pancreatic islets [55]. While the functional analysis of 
rs573225 in a reconstituted cell system can resolve the latter discrepancy (Fig. 4.5 and 
Fig. 4.6), it remains to be determined why this SNP fails to function as expected in islet-
derived cell lines. The HeLa cell experiments suggest that the action of rs573225 and 
rs2232316 on G6PC2 gene expression in vivo will be critically dependent on Foxa2 
levels. Whether Foxa2 levels differ between islet-derived cell lines and islets is unknown; 
however, Foxa2 levels are elevated in hepatoma cells as compared to liver [125]. 
Therefore the observed discrepancy may be limited to SNPs that affect Foxa2 binding. 
On the other hand, the observed discrepancy may reflect a broader problem with the use 
of islet-derived cell lines for such analyses. Interestingly, mouse G6pc2 fusion genes that 
are active in islet-derived cell lines in situ are only active in fetal and newborn but not 
adult mouse islets in vivo [75], suggesting that the islet-derived cell lines used for these 
analyses do not accurately mimic the behavior of adult islet beta cells in vivo. 
 Since elevated FBG and HbA1C are associated with an increased risk for the 
development of type 2 diabetes [95, 126, 127] and because G6PC2 is associated with 
variations in fasting glucose and HbA1C [43, 90, 91, 107-110, 119, 121, 122, 128], one 
would logically expect that G6PC2 would also be associated with increased risk for the 
development of type 2 diabetes. Indeed some studies have now shown such an 
association [90, 110, 128] and two very recent reports suggest that elevated G6PC2 
expression may be specifically linked to the onset, rather than the progression, of beta 
cell failure [129] as well as a long term deterioration in glucose homeostasis [43, 130]. In 
contrast, other studies have shown that in some populations G6PC2 is not associated with 
increased risk for the development of type 2 diabetes [119]. The molecular basis for these 
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differences is unclear. One possibility is that the reported association between G6PC2 
and type 2 diabetes is a false positive due to the use of relatively low sample sizes [90, 
110, 128]. Another possibility is that modifier genes, whose actions are population-
specific, determine whether variations in G6PC2 will influence susceptibility to type 2 
diabetes. 
 The observation that FPG is reduced in G6pc2 knockout mice led to the 
hypothesis that the glucose-6-phosphatase activity of G6PC2 opposes the action of 
glucokinase, which catalyses the conversion of glucose to glucose-6-phosphate [55]. 
Glycolytic flux has been shown to determine the S0.5 of glucose-stimulated insulin 
secretion (GSIS) and the existing paradigm in the islet field proposes that glucokinase 
alone is the beta cell glucose sensor [45, 131-133]. The significance of the G6pc2 
knockout mouse data is that they challenge this paradigm and suggest that G6PC2 is a 
fundamental inhibitory component of that sensor. Instead we hypothesize that a 
glucokinase/G6PC2 futile cycle acts as the beta cell glucose sensor determining 
glycolytic flux and the S0.5 of GSIS. If correct, the simplest scenario would be that a 
reduction of G6PC2 expression would result in a leftward shift in the concentration-
response curve for GSIS in which the S0.5 but not Vmax of GSIS was reduced. However, in 
humans G6PC2 SNPs that are associated with elevated FBG are associated with 
increased insulin secretion [59-61]. Because these SNPs are not associated with altered 
insulin sensitivity or glucose tolerance, altered pulsatility of insulin secretion has been 
invoked as a possible explanation for this paradoxical observation [60]. If correct, these 
data would imply that G6PC2 impairs the pulsatility of insulin secretion such that when 
G6PC2 expression is decreased pulsatility and consequently the efficacy of insulin 
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signaling are enhanced, resulting in a lower requirement for insulin secretion. Future 
studies using G6pc2 knockout mice should be able to resolve the impact of G6pc2 on the 
kinetic characteristics of GSIS and the pulsatility of insulin secretion. 
 In summary, our study provides genetic and functional evidence supporting an 
important role for the rs2232316 promoter variant, in addition to rs13431652 [96], as 
potentially causative SNPs that contribute to the association signal between G6PC2 and 
FPG, though the data do not preclude a significant contribution of the intronic variant 
rs560887, or other additional unidentified variants. However, the in situ functional data 
suggest a major limitation in the use of islet-derived cell lines to extend GWAS data 
through the identification of causative SNPs that is specific to rs573225. This is a 
potentially more broadly relevant concern since many of the other genes implicated in 
GWAS relating to type 2 diabetes and its associated quantitative traits genes are involved 
in beta cell function [134]. 
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CHAPTER V 
 
THE rs560887 SINGLE NUCLEOTIDE POLYMORPHISM LINKED TO 
VARIATIONS IN FASTING PLASMA GLUCOSE ALTERS G6PC2 RNA 
SPLICING 
 
 
Introduction 
 The recent spate of GWA studies in humans, previously discussed in detail, have 
consistently identified a variant in G6PC2 as the strongest common genetic determinant 
of FPG and HbA1C levels in terms of effect size and significance [90, 107-110, 119, 121, 
122, 128]. The rs560887 SNP, localized in the 3rd intron of G6PC2, may explain ~1% of 
the total variance in FPG within these genetic studies. In addition to its association with 
elevated FPG, the rs560887-G allele is also associated with decreased basal insulin 
secretion, as assessed by Homa%B, and increased risk of incidence of impaired fasting 
glucose over time using prospective data from the D.E.S.I.R. study [43]. The goal of the 
following experiments was to extend the data gleaned from GWA studies through 
molecular studies designed to assess the potential of rs560887 and two other SNPs, 
rs2232321 and rs35259259, to be causative, specifically by altering G6PC2 RNA 
splicing. Additionally, the presence and contributions of a non-consensus splice junction 
at the 5’ end of exon 4 was examined. 
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Results 
 
rs560887 alters G6PC2 RNA splicing 
 In higher eukaryotes, pre-mRNA splicing is mediated by multiple cis-elements in 
the pre-mRNA molecule. These elements comprise the branch point sequence, the 
polypyrimidine tract, the 5’ and 3’ splice sites and exonic/intronic splicing 
enhancers/silencers [85, 87, 135]. These elements bind a complex array of splicing 
factors that together form the spliceosome. rs560887 is located in the intron just 5’ of the 
exon 4 splice junction and sequence analyses reveal that rs560887 lies precisely in a 
branch point sequence, defined as the position where intron lariats form [85, 87, 135]. 
The human branch point consensus sequence yUnAy, where y is C or U, and it is 
typically located 21-34 nucleotides upstream of the 5’ end of an exon [136]. The putative 
branch point element 5’ of exon 4 has the sequence UUUAU and it is located 26bp 5’ of 
the exon. Both the sequence and location of this element are therefore consistent with this 
being a splicing branch point. 
 The SNP changes the sequence from UUUAU to UUUAC. While the change still 
matches the consensus [136] an analysis of the sequence of the RNA component of the 
small nuclear ribonucleoprotein (snRNP) U2, which binds the branch point element 
[135], demonstrates that the SNP nucleotide will form hydrogen bonds with a ‘G’ 
nucleotide in the U2 RNA. Since the ‘G’ will form three hydrogen bonds with the ‘C’ 
nucleotide and only two with the ‘U’ nucleotide, U2 binding should be stronger with the 
former. This then suggests that rs560887 has the potential to affect the strength of U2 
binding and hence splicing. A minigene strategy, in which splicing of individual exons 
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can be assessed, was used to address this hypothesis [137, 138]. Specifically we utilized 
the RHCglo minigene plasmid vector, which contains the Rous sarcoma virus promoter, a 
5’ exon with a splice junction, an artificial exon surrounded by intron sequences from the 
human beta-globin gene and a 3’ exon with a splice junction (Fig. 5.1) [139]. The 
artificial exon and surrounding human beta-globin gene intron sequences were replaced 
by G6PC2 exon 4 and ~300bp of surrounding intronic sequences. Two minigenes were 
constructed containing the alternate alleles of rs560887. 
 These minigenes were expressed in HeLa cells using transient transfection, RNA 
isolated 18 hrs post-transfection and cDNA generated. Using primers A and primer B 
(Fig. 5.1) and a radiolabeled dATP to be incorporated through PCR, splicing between the 
vector 5' and 3' exons and the inserted G6PC2 exon was assessed. PCR reactions were 
performed under conditions where amplification was in the linear range (Fig. 5.2) and the 
products (X and Y; Fig. 5.3) were resolved on non-denaturing polyacrylamide gels as 
described [140]. DNA sequencing confirmed the identity of these products and the 
presence of the predicted splice junctions. Figure 5.3 shows that the alternate alleles of 
rs560887 alter the relative abundance of products X and Y, with the rs560887-C allele 
promoting inclusion of G6PC2 exon 4. This is consistent with the genetic association 
between the rs560887-C allele, elevated FPG and the putative function of G6PC2 
suggesting that rs560887 is a potentially causative SNP. The combination of these 
functional data with the genetic data supports a direct connection between G6PC2 and 
FPG. 
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Figure 5.1.  Insertion of G6PC2 exons and products of the RHCglo minigene vector 
The RHCglo minigene vector comprises the RSV promoter, a 5’ exon, a 3’ exon, and Sal 
I plus Xba I restriction enzyme sites into which G6PC2 exon (Exon) 4 or 5 were ligated 
along with surrounding 5’ and 3’ intronic sequences (for exon 4) or just 5’ intronic 
sequences (for exon 5). RT-PCR was used to generate cDNA from the isolated RNA 
products, and PCR was used to quantitate the relative abundance of splice products X and 
Y using primers A and B. 
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Figure 5.2.  Linearity of PCR reaction for RHCglo minigene RNA products 
A RHCglo minigene vector containing exon 4 and one allele of rs560887 in intron 3 was 
transiently transfected into HeLa cells. Following RNA isolation and cDNA synthesis as 
described in Chapter II, the linearity of the PCR reaction involving primers A and B (Fig. 
5.1) was observed using increasing cycle numbers of 18, 22, 26, and 30.  
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Figure 5.3.  Alterations in G6PC2 exon 4 splicing by rs560887 
RHCglo minigene vectors containing the alternate alleles of rs560887 were transiently 
transfected into HeLa cells and RNA expression was quantitated as described in Chapter 
II. Results show the mean data from three experiments ± S.E.M. *P < 0.05. 
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rs2232321 also alters G6PC2 RNA splicing 
 rs2232321 is located immediately 3' of rs560887 and lies just outside the branch 
point element. However, by analogy with transcription factor binding elements where 
flanking sequence often affects binding affinity [141] we hypothesized that this SNP 
might also affect U2 binding and hence splicing. Using the same minigene strategy as 
described above, Figure 5.4 shows that the alternate alleles of rs2232321 alter the relative 
abundance of products X and Y, with the rs2232321-G allele promoting inclusion of 
G6PC2 exon 4. The magnitude of the effect was smaller than that seen for rs560887, 
consistent with the fact that, unlike rs560887, rs2232321 does not alter the sequence of 
the branch point element (compare Fig. 5.3 and Fig. 5.4). 
 
The effects of rs560887 and rs2232321 are dependent on the non-consensus exon 4 
splice junction 
 
 We have previously shown that in both mice and humans the 5’ exon 4 splice 
junction contains the non-consensus sequence tag/A [36, 74] instead of cag/G [142] 
(intronic sequence in lower case letters). We hypothesized that the presence of this non-
consensus splice junction may result in splicing being more susceptible to the influence 
of rs560887 and rs2232321. This hypothesis was tested using the same minigene 
approach as discussed above. Figure 5.5 shows that when the sequence of the non-
consensus 5’ exon 4 splice junction is converted to tag/G the inclusion of G6PC2 exon 4 
is strongly enhanced, despite the presence of the sub-optimal rs560887-T allele. This 
indicates that the influence of the alternate alleles of rs560887 and rs2232321 on G6PC2 
RNA splicing is strongly dependent on the presence of the non-consensus exon 4 splice 
junction. 
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Figure 5.4.  Alterations in G6PC2 exon 4 splicing by rs2232321 
RHCglo minigene vectors containing the alternate alleles of rs2232321 were transiently 
transfected into HeLa cells and RNA expression was quantitated as described in Chapter 
II. Results show the mean data from three experiments ± S.E.M. *P < 0.05. 
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Figure 5.5.  Dependency of the effects of rs560887 and rs2232321 on the non-
consensus exon 4 splice junction 
RHCglo minigene vectors containing the native (A) or consensus (G) exon 4 5’ splice 
junction were transiently transfected into HeLa cells and RNA expression was 
quantitated as described in Chapter II. Results show the mean data from three 
experiments ± S.E.M. *P < 0.05. 
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The alternate alleles of rs35259259 result in a frame shift and affect G6PC2 RNA 
splicing 
 
 rs35259259 is located at the 5’ splice junction of exon 5 and represents a deletion 
SNP, specifically the presence or absence of the exon 5 splice junction ‘G’ acceptor 
nucleotide. This SNP changes the sequence of the splice junction from cag/GCAT to 
cag/CAT (intronic sequence in lower case letters), which no longer matches the 
consensus cag/G [142]. We hypothesized that the presence of this non-consensus splice 
junction would abolish splicing. Because exon 5 is the terminal exon in the G6PC2 gene 
testing this hypothesis was more complex. However, we reasoned that the artificial 
minigene approach would still work if the minigene 3’ exon spliced to a cryptic splice 
site within exon 5 (Fig. 5.1). Figure 5.6 shows that cryptic splicing indeed occurred 
resulting in the generation of product X (Fig. 5.1). DNA sequencing revealed that the 
cryptic 3’ splice junction within exon 5 had been formed utilizing the G6PC2 exon 5 
sequence TC/gtga. This is only a partial match with the (A or T)G/gtaa consensus [142], 
which presumably results in inefficient splicing explaining why product Y > X (Fig. 5.6), 
in contrast to the exon 4 splicing experiments where product X >> Y (Fig. 5.2). Figure 
5.6 shows that deletion of the exon 5 splice junction ‘G’ acceptor nucleotide further 
reduces the abundance of product X; however, splicing was not totally abolished. DNA 
sequencing revealed that the minigene 5’ exon was now being spliced to G6PC2 exon 5 
using the non-consensus cag/CAT splice site described above. However, the product 
formed is now out of frame and would result in a truncated form of G6PC2 (207 versus 
355 amino acids) lacking 5 out of 9 transmembrane domains [36], which is presumably 
non-functional.  
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Figure 5.6.  Frame shift effects of the variants of rs35259259 on G6PC2 exon 5 
splicing 
RHCglo minigene vectors containing the alternate alleles of rs35259259 were transiently 
transfected into HeLa cells and RNA expression was quantitated as described in Chapter 
II. Results show the mean data from three experiments ± S.E.M. *P < 0.05. 
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Discussion 
 Genome-wide association studies have recently provided important new insights 
concerning the genetics of quantitative traits related to type 2 diabetes, such as FPG and 
haemoglobin A1C [43, 90, 91, 107-110, 119, 121-124, 128]. These GWAS data showed 
that the G6PC2 locus harbors the strongest common genetic determinant of FPG and 
HbA1C levels in terms of effect size and significance. The studies described here represent 
a key step in extending these discovery phase GWAS data by establishing a functional 
link between the genetic variation in the G6PC2 locus and variation in FPG. Specifically 
we used minigenes, in which splicing of individual exons can be assessed [137, 138], to 
show that a common variant, rs560887, that is located in the 3rd intron of G6PC2 and 
which may explain ~1% of the total variance in FPG [90, 107, 109, 110, 113, 119, 121, 
122, 128], modulates G6PC2 RNA splicing (Fig. 5.1 and Fig. 5.2). 
 In a previous study we examined the contribution of two G6PC2 promoter SNPs, 
rs13431652 and rs573225, to the association signal between G6PC2 and FPG [96]. 
Genetic data support a potential role for both rs13431652 and rs573225 as causative 
SNPs linking G6PC2 to variations in FPG. The rs13431652-A allele was associated with 
increased FPG and elevated promoter activity, consistent with the putative function of 
G6PC2 in pancreatic islets. In contrast, the rs573225-A allele was associated with 
increased FPG but reduced promoter activity, at odds with the putative function of 
G6PC2 in pancreatic islets [96]. One interpretation of these data is that human G6PC2 
and mouse G6pc2 have opposite effects on FPG such that it is the behavior of the 
rs13431652 SNP in tissue culture cells that does not accurately reflect its effect on 
G6PC2 gene transcription in vivo. The other interpretation of these data is that the 
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behavior of the rs573225 SNP in tissue culture cells does not accurately reflect its effect 
on G6PC2 gene transcription in vivo. The studies described here strongly support the 
latter, simpler interpretation. Thus the rs560887-C allele promotes inclusion of G6PC2 
exon 4 and presumably higher G6PC2 protein expression. This would lead to increased 
G6P to glucose cycling and a reduction in glucose-stimulated insulin secretion. The 
splicing data are consistent with the genetic association between the rs560887-C allele 
and elevated FPG and the putative function of G6PC2. The functional data therefore 
suggest that rs560887 is a potentially causative SNP and the combination of these 
functional data with the genetic data support a direct connection between G6PC2 and 
FPG. 
 In the initial characterization of mouse [32] and human [36] G6PC2 mRNA, 
various splice forms were observed in islets. The most common human G6PC2 variant 
lacked exon 4, an observation that could be explained by the fact that, in contrast to 
G6PC and G6PC3, the sequence of the 5’ exon 4 splice junction of G6PC2 does not 
match the consensus [35, 39]. Interestingly, the effect of rs560887 is dependent on the 
presence of this non-consensus junction (Fig. 5.5). Other G6PC2 variants have also been 
detected that lacked exon 2, exons 3 plus 4, and exons 2, 3, and 4 together [36]. Human 
G6PC2 splicing was subsequently studied in greater detail in thymus and spleen 
following the identification of IGRP/G6PC2 as an autoantigen in type 1 diabetes [143]. 
Although the biological significance of the observation is unknown, it is fascinating that 
80% of autoantigens show non-canonical splicing compared to 1% in the general 
population [144]. One intriguing possibility is that some parts of G6PC2 may escape 
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central tolerance and thus contribute to autoimmunity and type 1 diabetes in the periphery 
[143]. 
 In summary, our study provides functional evidence supporting an important role 
for the intronic rs560887 variant as a potentially causative SNP that contributes to the 
association signal between G6PC2 and FPG and demonstrates the essential role of 
combining genetic and functional data in assessing the importance of individual human 
genetic variants. The genetic data do not preclude a contribution of additional variants. 
Indeed, we have previously shown that two G6PC2 promoter SNPs, rs13431652 and 
rs573225, contribute to the association signal between G6PC2 and FPG [96] and we 
demonstrate here that two additional SNPs, rs2232321 and rs35259259, affect G6PC2 
pre-mRNA splicing. Future genetic analyses will be required to establish the contribution 
of these SNPs to the association signal between G6PC2 and FPG.  
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Thesis Summary 
 The experiments described within this thesis served to elucidate the role of 
various G6PC2 SNPs in the regulation of G6PC2 transcription and pre-mRNA splicing. 
A number of these SNPs had been previously associated by GWA study with variations 
in FPG and HbA1C [43, 90, 107-110, 119, 121, 122, 128]; however, the affect of these 
allelic variations had yet to be analyzed at a molecular level. The experiments were 
designed to determine what effect these SNPs have on G6PC2 transcription and splicing. 
Using a combination of transfection and reporter assays, it was demonstrated that 
the rs13431652 and rs573225 SNPs affect binding of NF-Y and Foxa2, respectively [96]. 
A change in G6PC2 transcription was observed using fusion gene assays, with the 
introduction of the minor allele of rs13431652 resulting in a decrease in transcription and 
introduction of the minor allele of rs573225 resulting in an increase in fusion gene 
transcription. In the case of rs13431652, the fusion gene data show that the rs13431652-
A allele increases transcription, which correlates with the GWA study association of this 
allele with elevated FPG [96], consistent with the function of G6PC2. However, the data 
obtained for rs573225 are at odds with this model. While the rs573225-A allele is highly 
associated with elevated FPG by GWA study and enhances Foxa2 binding in EMSAs 
[96], the lower fusion gene expression observed with this allele fails to support the 
function of G6PC2 and the reduced FPG seen in G6pc2 knockout mice [55]. Thus, these 
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functional data support a causative role for rs13431652 but not rs573225. 
In addition to rs13431652, the experiments of chapter IV provided both genetic 
and functional data supporting the role of rs2232316 as a potentially causative SNP. 
Conditioned regression model analyses were unable to assign independence of the signal 
from rs2232316 and rs573225 because the two variants are in high LD. This implies that 
the two associations actually represent a single signal and that both SNPs may be 
causative variants. Gel retardation studies elucidated not only specific binding of Foxa2 
to the rs2232316 locus, but also a decrease in binding efficiency of the rs2232316-G 
allele for Foxa2 compared to the rs2232316-A allele. This variation was extended to 
fusion gene analysis in βTC-3 cells, where the A allele of rs2232316, in the context of the 
-324 to +3 G6PC2 promoter region, was found to increase promoter activity by 
approximately 50% compared to the rs2232316-G allele. Thus the genetic and functional 
data for this particular SNP correlate, and, when taken as a whole, support the potential 
causative role of rs2232316 linking G6PC2 to variations in FPG. 
Because of the correlation between the fusion gene experiments and the genetic 
associations for rs2232316, two explanations for the contradictory results for rs573225 
exist. In the instance that the fusion gene data for rs573225 truly matches the effect of the 
SNP in vivo, rs573225 could not be the causative variant in this promoter region as it 
simply does not correlate with the GWA study associations between the SNPs and FPG. 
Its association with variations in FPG would therefore have been due to its interaction 
with rs2232316, the action of which would serve to mask the variations in FPG 
contributed by rs573225. More likely, this SNP does not function correctly in our fusion 
gene experiments, as illustrated by the differing results found in the analyses in βTC-3 
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and HeLa cells. 
Due to this potential limitation of islet-derived cell lines with respect to rs573225, 
it was decided that both rs573225 and rs2232316 would be re-analyzed in a reconstituted 
cell system comprised of HeLa cells co-transfected with the G6PC2 fusion genes and 
expression vectors encoding various islet-enriched transcription factors. The results of 
these experiments showed the opposite effect for the rs573225-G allele, which was here 
associated with reduced, rather than increased, G6PC2 fusion gene expression. A 
similarly opposite effect for rs2232316 was seen in this system compared to βTC-3 cells, 
with the rs2232316-A allele being associated with reduced G6PC2 fusion gene 
expression in the reconstituted HeLa cell system. Overexpression of Foxa2 in the system 
served to blunt the effect of the alternate alleles of rs573225 but returned the results with 
the alternate rs2232316 alleles to those seen in βTC-3 cells. These results imply that, in 
specific circumstances, the rs573225-G allele fusion gene results correspond with the 
genetic data, but that the in vivo action of both rs573225 and rs2232316 on G6PC2 
expression hinges on the concentration of Foxa2. 
While a number of these G6PC2 SNPs have been associated with variations in 
FPG, the strongest association with FPG in multiple GWA studies was observed with 
rs560887. However, this SNP does not lie in the promoter or a proposed enhancer of 
G6PC2. Upon further examination, rs560887 was found to exist in a branch point 
sequence of intron 3. By utilizing a minigene plasmid developed by Dr. Thomas Cooper, 
the RHCglo plasmid vector, changes in the splicing of individual exons in response to 
allelic variation was assessed. A change from the rs560887-T allele to the -C allele 
resulted in increased inclusion of exon 4, possibly due to a stronger association of the U2 
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snRNP component of the spliceosome, which is consistent with the genetic association of 
this allele with elevated FPG and the proposed role of G6PC2. Another SNP, rs2232321, 
residing immediately 3’ of rs560887, was also found to alter splicing, with the 
rs2232321-G allele increasing the product containing exon 4, albeit to a lower degree 
than that observed with the rs560887-C allele. 
The presence of a non-consensus 5’ exon 4 splice junction was hypothesized to 
influence the magnitude of splicing variation seen with both rs560887 and rs2232321. By 
using the same minigene approach, a change of the splice junction to the consensus tag/G 
resulted in a significant increase in exon 4 inclusion. This therefore implies that, while 
rs560887 and rs2232321 are able to influence G6PC2 pre-mRNA splicing, their effects 
are amplified due to the presence of the non-consensus 5’ exon 4 splice junction. Another 
SNP, rs35259259, lies at the 5’ splice junction of exon 5, but rather than changing alleles 
this is a so-called “indel” SNP that affects the presence or absence of a base at this 
location. Such a change results in a frame shift mutation of exon 5, presumably creating 
another instance of a non-functional G6PC2 protein due to the loss of 5 out of 9 
transmembrane domains. Through minigene analysis, it was found that a deletion at this 
SNP results in a frame shift and a truncated protein. However, due to the extreme rarity 
of this SNP, no genetic or metabolic associations have been made, though because of its 
nature, it is believed that a deletion at rs35259259 would also be associated with a 
significant reduction in FPG, as is the case with the rs560887-T allele. 
As a whole, the experiments and data described within this document sought to 
elucidate the molecular roles of various SNPs within the G6PC2 gene. Through these 
analyses, strong support was generated for a role of rs13431652 and rs2232316 as 
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causative variants, while the data derived for rs573225 likely indicates a limitation in the 
use of islet-derived cell lines and a causative label could not be applied. Additionally, the 
variant most strongly associated with changes in FPG, rs560887, and other intronic 
variants were revealed to affect the splicing of G6PC2 pre-mRNA in a manner that 
further corroborates the role of G6PC2 as a regulator of FPG. 
 
Future Directions 
 GWA studies performed more recently have elucidated a lack of association 
between FPG in a normoglycemic range (70-100mg/dL) and CAM [145], as well as a 
lack of influence by the SNPs in G6PC2 on fasting glycemia in patients with elevated 
FPG [129]. These studies have created a link between FPG and CAM not in an entirely 
linear manner, but with a range of FPG on the low end of the scale that does not associate 
with an increased risk for CAM, before a linear increase in association is seen at higher 
FPG. The direct role of G6PC2 in CAM has yet to be studied, but such conflicting results 
necessitate further consideration of the results regarding this interaction. 
 The results described in this thesis have begun to elucidate the roles of multiple 
SNPs within the G6PC2 gene, but while the specific SNPs analyzed have either been 
associated with variations in FPG (rs560887, rs573225, rs13431652, rs2232321), or 
occupy a location known to be critical for a cellular process (exon 4 splice junction, 
rs35259259), numerous other SNPs have been found in G6PC2. Though many of these 
are likely to prove non-causative, the potential exists that additional causative SNPs exist. 
In-depth genetic analysis and association studies have proven extremely useful in the 
search for relevant SNPs, and an increase in subject number for these studies, critical to 
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increase power, may continue to produce significant associations of different SNPs 
within G6PC2 and FPG. Examination of the G6PC2 promoter using a program such as 
MatInspector may uncover the presence of SNPs with the potential to affect transcription 
factor binding. The influence of these alleles could then be tested as described in chapters 
III and IV. 
 In addition to further analysis of promoter SNPs, other polymorphisms found 
within the open reading frame of G6PC2 can be scrutinized for their effect on splicing 
efficiency or protein function. In the case that a SNP is purported to affect association or 
function of the spliceosome, an experimental approach similar to that of chapter V could 
be implemented to determine whether aberrant splicing occurs. As the glucose-6-
phosphatase activity of G6PC2 has been successfully demonstrated in vitro, the assay 
could be used to examine whether non-synonymous SNPs affect enzyme activity. Thus, 
while the structure of G6PC2 and the glucose-6-phosphatase holoenzyme are unknown, 
SNPs causing a change in the amino acid sequence of G6PC2 may alter the ability of the 
enzyme to hydrolyze G6P. These changes could then be quantified by comparing the 
activities in the presence of either the major or minor allele of each SNP. 
 Further investigation of the in vivo nature of the SNPs discussed in this document, 
namely rs35259259, may also be pursued. As the rarity of this SNP has precluded 
previous metabolic analyses, a continuation of the search for individuals possessing this 
allelic deletion may provide vital information associating this locus with significant 
variations in FPG. Large databases, including BioVU at Vanderbilt University, now exist 
to provide access for researchers to the medical records and genomic sequences of de-
identified patients at the Vanderbilt University Medical Center. By utilizing this resource, 
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a search for individuals possessing the deletion at rs35259259 will provide access to any 
medical information gleaned from their medical examination. Should this usage of 
BioVU be undertaken, information regarding this SNP and the correlating FPG values 
would prove invaluable. 
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